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ABSTRACT
Personalized medicine, seen as the solution to address the variability among the 
individuals, is the movement which proposes customization o f medical procedures based 
on the need o f the patient during the stages o f prevention, diagnosis, treatment, and 
follow up. As the technology in medicine expands and newer methods o f diagnosis and 
treatment are introduced in the clinic, real time data from the procedures is critical to 
assess the performance at point o f care. Real time feedback, through collection o f data at 
point o f care would help make informed clinical decisions, potentially improving the 
efficacy o f the treatment. In this dissertation, the development o f instrumentation and 
data analysis protocols for rapid feedback during clinical application o f antimalarial 
quinine, antifungal amphotericin b, and gold nanoparticles are discussed.
Nanoparticles have emerged as powerful treatment modality in many biomedical 
sensing and therapeutic applications. The application o f intravenously delivered near- 
infrared absorbing gold nanoparticles for photothermal ablation o f solid tumors has been 
previously reported. A lot o f research has been devoted to the development and 
characterization o f gold nanoparticles for clinical applications, and with multiple clinical 
trials underway, ongoing pre-clinical research continues towards better understanding the 
in vivo interactions o f these particles. The current need for a set o f best practices in 
nanomedicine to increase the in vivo treatment efficacy was the rationale for this 
investigation.
In an effort to enable informed decisions at point-of-care applications, within a 
relevant time frame, instrumentation for real-time plasma concentration (multi­
wavelength photoplethysmography) and protocols for rapid elemental analysis (energy 
dispersive X-Ray fluorescence) o f tumor tissue samples have been developed in a murine 
model. This dissertation describes the implementation and characterization o f the novel 
pulse photometer in terms o f its sensing application, and outlines the development o f a 
protocol for quantifying the concentration o f gold in excised tumors in a clinically 
relevant time frame (< 24 hours) using energy dispersive X-ray fluorescence protocol 
developed for this specific purpose. In this dissertation, we evaluate the relationship 
between circulation pharmacokinetics and tumor accumulation using gold nanorods 
which passively accumulated in a murine subcutaneous colon cancer model. The plasma 
concentration o f the near-infrared absorbing nanoparticles was monitored in real-time 
using a novel pulse photometer. The data collected was used to build a bio distribution 
curve and to calculate circulation half-life as well as the area under the curve (AUC) 
using an exponential decay model.
New research efforts are described, which focus on adjuvant therapies that are 
employed to modify circulation parameters, including the AUC, o f nanorods and gold 
nanoshells. Based on the premise that nanoparticles are primarily removed from the 
blood by the reticuloendothelial system (RES), this dissertation also demonstrates the 
effects o f RES blockade to prolong the circulation o f gold nanoparticles tested on a 
murine model via intravenous administration o f A.-carrageenan at a concentration o f 50 
mg/kg. Transient RES blockade techniques have the potential to enhance the circulation 
time o f agents that are cleared by the RES. Preliminary studies demonstrated a greater
than 300% increase in average AUC using a reticuloendothelial blockade agent against 
the control groups.
Further expansion o f the application o f the novel pulse photometer was achieved 
by modification o f the device for in vivo sensing o f other clinically applicable molecular 
drugs such a quinine and amphotericin b. This dissertation reports the development o f a 
non-invasive optical system capable o f reporting the in vivo vascular concentration o f 
these molecular drugs in near real time.
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1.1 Photoplethysmography and Monitoring of 
Nanoparticles and Other Drugs
The medical advances in recent decades can be described in terms o f the 
development o f personalized or individualized diagnostic and therapeutic techniques 
which address “ the great variability among individuals" f 1], This recent drive towards 
personalized medicine, suggests the need for near-real time clinical evaluation o f the 
progression and efficacy o f therapies. The progression o f medicine, especially the clinical 
processes that involve drug delivery, has evolved to a point where quantitative 
assessment o f various factors is considered critical to the outcome o f the therapy. Since 
each individual reacts differently to a particular drug, and there is significant patient-to- 
patient variability, even within a small group o f patients, real time monitoring o f and 
verification o f pharmacological variables such as dose, circulation, and clearance, is 
necessary. This type o f monitoring is particularly important in the case o f drugs which 
carry harmful side effects in case o f overdosing.
In an effort to verify the dose, and investigate the real time in vivo circulation o f 
optically resonant gold nanorods, a non-invasive optical device was developed [2], [3], 
The device, referred to as a pulse photometer, uses the technique o f multi-wavelength
photoplethysmography, which is the basis o f instrumentation in pulse photometry, and 
pulse dye densitometry.
Using the pulse photometer, we were able report the circulation o f gold nanorods 
and oximetry for six hours post-injection in mice with no anesthesia. The initial rationale 
for developing this type o f instrument relates to the need for increased quality and 
reproducibility o f nanoparticle-based therapies. The driving rationale was that the 
important step towards the clinical utility o f these nanoparticles is to verify that the 
nanoparticles have been delivered to the blood at the expected dose and have an adequate 
circulation time so that they have the opportunity to accumulate at the target sites. This 
data could also lend credibility to other metrics showing the nanoparticles had been 
manufactured according to specifications.
1.2 Photoplethysmography, Beer-Lambert’s Law 
and Optical Density
The plethysmogram is a physiological signal that arises from the small change o f 
volume in tissue due to a pulsatile phenomenon. This signal can be measured using light 
by measuring small changes in its reflection or transmission. Measuring this signal using 
the technique o f detecting light is called photoplethysmography (PPG) and this technique 
has been utilized in many medical applications and this technique has been developed 
over the past few decades [4],
Since the optical properties o f the pulsatile tissue are determined by looking at the 
individual components o f the signal, PPG can be used to gain spectral information about 
the pulsatile constituents o f the tissue. A mass o f tissue perfused with blood w ill contain
optically extinguishing components that are relatively constant in volume (such as 
muscle, bone, and venous blood), and pulsing arterial blood.
When we examine the small changes in the attenuation o f light interacting with 
the tissue, the contribution o f only arterial blood is isolated from the other components by 
isolating the pulsatile part o f the signal as shown in Figure 1 -1.
Absorption due to pulsatile blood (AC signal)
Absorption due to static tissue and venous 
blood (DC signal)
Figure 1-1: A conceptual schematic o f the sources o f absorption o f light as measured by 
the pulse photometer.
It is for this reason that PPG is applicable to the analysis o f the optically 
extinguishing properties o f arterial blood. A graphical illustration o f the transmission 
mode measurement o f this pulsatile nature o f tissue can be seen in Figure 1 -1. In the 
preceding figure, i f  we consider I0 to be the intensity o f light o f a single wavelength 
entering the tissue, and I be the intensity o f light that reaches the detector, then the 
absorption o f light (A) caused by the tissue is defined as:
A = - ln ( f ) .  Eq. 1-1
\ l 0 /
Beer-Lambert’ s Law states that the intensity o f light decreases exponentially as a 





photons in an absorptive medium for a particular wavelength is defined as the absorbance 
(equivalent to absorption defined above), which is:
A ^ r.c .d , Eq. 1-2
where ( = molar extinction coefficient o f the material for that wavelength, 
c = concentration o f the absorptive material, 
d = thickness o f the sample (path length).
In this case, we ignore specular reflection and combine absorption and scattering 
into one term, the equation can be rearranged in terms o f the total extinction, which is 
represented by the quantity A. Since it is a ratio o f intensities, the measured value 
extinction for a specific wavelength is unitless. This value is also known as the optical 
density o f the sample. In conventional spectroscopy, because o f the size o f the cuvettes 
(sample holders) used, the value is typically defined as optical density/cm or optical 
density/mm.
The PPG quantifies the concentration using the Beer-Lambert Law and the 
principles o f pulse oximetry theory, focusing on the absorption due to the pulsating 
medium measured in a vascularized mass o f tissue. The particular descriptions o f the 
theory behind the operation o f the device is further explained in Section 2.2. This was 
implemented to find the concentration o f gold nanoshells in vivo in murine models across 
the therapeutically relevant concentration range [2], The device uses off-the-shelf 
optoelectronic components in conjunction with a LabVIEW virtual instrument (V I) with 
an algorithm based on Beer-Lambert’s Law in a multi-spectral method designed to 
elucidate the concentration (in optical density) o f oxy- and deoxy-hemoglobin and the 
nanoparticles simultaneously in the blood. This device was reported to measure the
5
optical density o f particles that are absorbent between 600 -  940 nm. longer than the 
major absorptive bands o f hemoglobin [3J.
Expanding on the current application o f the pulse photometer, the prototype was 
modified to monitor the in vivo circulation o f other clinically relevant molecular drugs in 
real time. It was decided to examine quinine and amphotericin b. focusing on the current 
clinical needs related to maintaining the dose within the therapeutic window and concerns 
o f potential toxicity [5] and the widespread application o f these drugs. The rationale was 
to improve treatment reproducibility as we precisely control and verify the delivered 
dose. In addition, we also aimed to quantify the clearance properties o f the drug in real­
time allowing for better control o f the dose within the therapeutic window. This report 
presents the feasibility test o f the system to quantify the concentration o f quinine, 
delivered intravenously at a therapeutically relevant dose.
1.3 Application of Nanoparticles in Development 
for Cancer Therapies
Empirical evidence has shown that cancer manifests itself as solid tumors about 
85% o f the time, and therefore, solid tumors are an area o f interest for a lot o f research 
[6]. The successful outcome o f tumor treatments often depends on physicians’ experience 
and available techniques because o f lack o f quantifiable metrics in the diagnostic and 
treatment phase [7], [8], Although survival rates have improved over the past few 
decades, with a one-year’ s survival rate going from 69.9% in 1975 to 81.8% in 2008, and 
a 10 year survival rate going from 41.9% in 1975 to 60.6% in 1999. much o f cancer 
therapy relies on qualitative assessment o f progression o f treatment parameters [9], [10], 
[11]. During the treatment, i f  surgical removal is not feasible for tumors that lie near
6
sensitive tissues, such as head, neck, and brain, or those that have metastasized, the 
treatment is continued with radiation or chemotherapy [121. Chemotherapy usually 
involves intravenous injection o f a therapeutic drug (which is generally toxic) and relies 
on the high metabolic activity o f tumors to absorb the chemotherapeutic agent quickly 
113|. In recent years, research has been done towards the efficacy o f less systemically 
toxic chemotherapy drugs, and Herceptin was found to exhibit very little toxicity in 
human trials [14], However, the uptake and retention o f traditional chemotherapeutic 
small/macro-molecules can be hindered by several physiological factors in the tumors 
[ 15J, which in turn might lead to side effects.
The high influence o f local physiological factors on drug uptake caused the 
scientific community to study the anatomical and physiological characteristics o f tumors 
in recent decades [16], [17], [18], However, these characteristics vary with tumor size, 
type, and location [19], [20], and identifying usable metrics that help in specific drug or 
nanoparticle design have been difficult to achieve. Although many empirical studies have 
pointed to different factors that influence uptake in some tumors [21 ]. these studies do 
not necessarily apply to other particles or conditions.
Custom designed nanoparticles have recently emerged as a powerful tool in many 
biomedical applications [22, 23]. In particular, several classes o f nanoparticles have been 
employed as cancer therapy agents [24], These particles can have architectures o f varying 
complexity, achieved by various chemical techniques usually performed in specific 
sequences to add complexity and functionality, depending on their specific applications, 
some o f which are described further.
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One class o f nanomaterials used for drug delivery are hydrogels, which are 
networks o f cross-linked polymer chains that are hydrophilic and are commonly used as 
tissue scaffolds. Several studies have been conducted using cross-linkers that w ill 
degrade under specific conditions (such as change in pH, or temperature), usually to 
release an encapsulated drug. Tauro et al. have demonstrated potential use o f poly 
(ethylene glycol) diacrylate (PEGDA) hydrogels to deliver chemotherapeutic agents to 
highly specific sites, and for use in treatment o f glioblastoma [25].
Polymeric nanoparticles are developed and are similar in nature to the hydrogel 
nanoparticles in the manner o f drug release. The polymeric nanoparticles are being made 
from polymers which erode under certain conditions to release an encapsulated drug and 
then disappear. Poly (e-caprolactone), poly (lactic acid), poly (glycolic acid) and their 
copolymers are a few examples o f the polymers under investigation for use in cancer 
therapy. The use o f polymeric nanoparticles could help in the location specific delivery 
o f chemotherapeutic agents, decreasing systemic toxicity, and improving patient 
outcomes [26].
Liposomes consist o f a lipid bilayer and are usually spherical, creating a hollow 
core used for the encapsulation o f drugs. This method is advantageous because it takes 
advantage o f the ability o f liposomes to preferentially accumulate in tumors due to the 
Enhanced Permeability and Retention (EPR) effect. This preferential accumulation in 
tumors allows for the control o f the dosage o f the encapsulated chemotherapeutic agent, 
enabling it to be given in lower doses, and be less systemically toxic while retaining the 
desired concentration and effect in the target tumor. Liposomes also allow for the control 
o f characteristics such as bioavailability, size, drug release rate, and dosing schedule,
8
which gives them a lot o f flexibility in their application. In 1990, The United States f  ood 
and Drug Administration (USFDA) first approved this type o f therapeutic agent as 
DOXIL (liposomal doxorubicin) [21]. Some o f the nanomaterials currently found in the 
market for cancer therapies are nanocarrier-based drugs. A few examples are Zevalin, 
Bexxar, Myocet, Zinostatin, Stimalmer, Oncaspar. Ontak, and Abraxane, which are drug 
carriers that include protein conjugates, immunoconjugates. and liposomes [28J. 
Additional types o f metal nanomaterials, such as Auroshells (gold nanoshells) and 
Combidex (iron oxide nanoparticles), are currently undergoing clinical trials for cancer 
therapy [29], Gold nanoparticles have unique optical properties that allow for non- 
invasive, real-time monitoring o f nanoparticle concentration in the blood [30], [2], [3],
Metrology and imaging technologies that are capable o f quantitatively 
characterizing the properties o f the nanoparticles have enabled the development o f the 
first round o f nanomedical technologies at an experimental or prototype level. However, 
the key characteristics that make a type o f nanoparticle treatment successful are yet to be 
recognized. Most o f the current research in nanoparticle based therapy is focused on 
various applications o f the nanoparticles for very specific purposes. Most o f the in vivo 
characteristics are interactions o f different kinds o f particles have yet to be studied. 
Although many nanoparticles are increasingly being manufactured for various purposes, 
with variations in size, shape, surface charge, surface coatings, ligands, depending upon 
the application, the physiological conditions that affect the accumulation and ultimately 
efficacy o f the therapeutic agents are rarely investigated.
Whatever type o f nanoparticle is chosen, the efficacy o f the treatment is 
determined by the ability to exploit the natural differences between cancerous and healthy
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tissue for the selective delivery to tumor cells in order to reduce damage to healthy cells. 
Most solid tumors are characterized by an abnormal vasculature and the lack o f 
functioning lymphatic vessels [16]. Studies have demonstrated that the vasculature o f 
some tumors is quantifiably different from normal tissue in terms o f permeability, size, 
the lack o f a complete basement membrane, and abnormally large inter-endothelial 
junctions [6], [16], and these differences are commonly exploited for passive delivery o f 
therapeutic agents via the enhanced permeability and retention effect (EPR). Thus, a 
careful study o f all these factors is important in order to take better advantage o f those 
properties resulting in an increased delivery while minimizing the effect o f those that 
would make the delivery less effective.
1.4 EPR Effect and Passive Targeting
The EPR effect is a commonly found defect in the vessel walls o f the tumors. It is 
caused by the high metabolic and growth rate o f the tumor tissue compared to the healthy 
tissue. The high demands o f nutrients in the tumor leads to rapid expansion o f vasculature 
along the tumor, which is aided by the secretion o f various growth factors, which is 
largely unregulated by the body. This lack o f regulation leads to poorly formed vessels 
and defective basement architecture allowing larger particles and molecules to escape the 
vasculature in these areas. This also caused the lymphatic drainage in areas around the 
tumor area to be sub-optimal. These larger particles are not able to escape the well- 
formed (healthy or non-tumorous) vasculature [31]. Passive tumor targeting is a 
technique to target tumors with therapeutic agents with the aid o f the EPR effect. This 
effect, in combination with the poor lymphatic drainage, creates an environment where 
specifically sized particles can preferentially accumulate, compared to normal tissue.
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Different modeling efforts in the past have suggested that the pore size is more important 
than the particle size for effective extravasation [32], Reports have suggested that pore 
size can be effectively modified by several methods including hyperthermia [32], [33].
1.5 AuroShell® Cold Nanoparticles
AuroShell® Particles are spherical particles with a dieletric core with a thin gold 
shell. The ratio o f core to coating gives the nanoshell’s tunable optical properties [34]. 
These particles (diameter o f approximately 155 nm) and nanorods (14 x 45 nm) have 
demonstrated utility in cancer therapies through the use o f the tunable optical properties. 
The therapy involves the intravenous injection o f gold nanoparticles and passive 
accumulation in tumor tissue. Once accumulation is complete, the particles are exposed 
to a specific wavelength o f light (by fiber optic), which excites and heats the 
nanoparticles, killing the tumor. This photothermal ablation o f the tumor has two major 
advantages: killing the tumor along vascular lines (cutting the tumor o ff from its source 
o f nutrients) and preferentially killing the tumor to minimize damage to healthy tissues 
surrounding the tumor. Once the tumor dies, the cells are disposed o f by the immune 
system [34]—[36], These plasmon resonant gold nanoparticles are used in tumor treatment 
and as contrast agents and have specific optical properties in the near infrared spectrum 
making them ideal for modem cancer therapy and optical imaging [37], In the treatment 
o f tumors, it is essential that nanoparticles be designed that w ill effectively deliver 
treatment, whether it is a drug or the nanoparticle itself, to the tumor preferentially to 
avoid collateral damage to normal tissue. So, the first step towards ensuring the 
preferential accumulation o f these nanoparticles is to make sure that the nanoparticles 
have a long enough circulation time so that they can be accumulated at the target sites.
1.6 Research Need and Presented Research
The research plan was proposed with the previously described clinical need and 
concerns, which gave rise to certain specifications to the instrumentation to be 
implemented, which are summarized in Table 1-1.
Table 1-1. List o f design specifications and rationale outlined in Section 1.5.
Objective Clinical need Design Specification






variability (in terms o f 
dosage, bioavailability, 
and uptake) in 
therapeutic 
nanoparticles.
Develop a population model for 
gold nanoparticles to establish a 
relationship between dose, 




method to rapidly 
quantify the 
accumulation o f gold 
nanoparticle in the 
tumor.
Develop a protocol for 
elemental analysis o f gold in 
tumor tissue using EDXRF 
(Energy Dispersive X-Ray 
Fluorescence), sensitive in the 0- 
50 ppm range, rapid enough to 





assessment o f the 
delivery o f dose in gold 
nanoparticle therapy.
Use o f novel multi-wavelength 
photoplethysmograph for direct 
dose verification and real-time in 
vivo sensing of circulating 
nanoparticles.
of treatment RES modulation
Provide a means 
to modulate the AUC and 
clearance to increase 
exposure time of 
nanoparticles.
Develop a safe protocol 
for temporary RES blockade, for 
the modulation of AUC and, 





application of the current 
prototype into real-time 
detection o f other 
clinically relevant 
molecular drugs.
Modify the current 
prototype to detect real-time in 
vivo detection of anti-malarial 
quinine and anti-fungal 
amphotericin b, within the limits 
o f their clinical doses.
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One important issue to address in nanoparticle therapy is the immune response o f 
the body after the in vivo application. Unmodified nanoparticles, when introduced to the 
body intravenously, w ill elicit an immune response resulting in rapid removal. Depending 
on the size and composition o f the nanoparticles, this can be either via renal excretion i f  
the particles are small enough, or cell mediated by the reticulo-endothelial system (RES). 
Primarily, the nanoparticles are removed from the vasculature by tissue macrophages in 
the liver and spleen called Kupffer cells. These cells can quickly identify and eliminate 
nanoparticles via phagocytosis [38]. The rapid removal o f nanoparticles from the 
bloodstream limits their potential application in control target delivery [39], Although the 
attachment o f PEG has been shown to increase the circulation time o f several types o f 
nanoparticles dramatically [40], which is usually reported as the circulation half-life o f 
the particle assuming an exponential decay in concentration over time, a detailed model- 
based study over the dynamics o f circulation o f these particles in the body has not been 
conducted yet. A detailed study that investigates the effect o f various hemodynamic 
variables on the final accumulation o f the tumor has not been performed.
In addition to several clinical factors that affect tumor uptake, researchers need to 
know the bioavailability and bio distribution o f the nanoparticles in order to ensure that 
they reach the target site, for which the real time monitoring o f the nanoparticles in vivo 
is required. A potential way to enhance the outcome during therapy is to increase 
feedback through additional clinical signs during the accumulation and treatment phases. 
Nanoparticle systems can be coupled with individualized pharmacokinetics and elemental 
analysis o f ex vivo tissue to confirm uptake and retention into the tumor. Concurrently, 
innovative medical devices are being developed to provide near-instantaneous
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pharmacokinetic feedback [35], suggesting the need for an elemental analysis technique 
that provides similarly rapid quantitative feedback o f biodistribution. These analyses 
could assess when, and to what degree, the particles were accumulating in the tumor, or i f  
they were being eliminated by the reticuloendothelial system (RES). The use o f rapid 
elemental analysis coupled with real-time pharmacokinetic measurements could help 
predict the most appropriate time for animal or human ablation (e.g. photothermal) o f the 
tumor. For animal studies, a faster technique can have a major impact for companies 
involved in nanomaterial quality control and product development.
Over the years, different ex vivo techniques have been implemented to monitor 
the nanoparticle accumulation and distribution in the body. The standard accepted 
method o f determining gold concentration is considered to be Instrumental Neutron 
Activation Analysis (INAA), which has been shown to be effective in determining the bio 
distribution o f gold nanoshells [41]. However, this technique is not useful for a clinical 
setting because o f the time delay (up to two weeks) in the processing and analysis o f the 
samples, whereas during patient care and treatments, almost instantaneous quantitative 
values are needed to make a decision on treatment. We posit that the Energy Dispersive 
X-Ray Fluorescence (EDXRF), with a suitable sample preparation and handling protocol, 
w ill be a suitable method for ex vivo analysis o f gold nanoparticles in biopsy samples in a 
clinically relevant time frame.
Since the particles are optically active, their optical absorbance and scattering 
properties can be exploited to monitor them [42]. This method applies Dynamic Light 
Scattering (DLS) to correlate the ration o f the scattering o f the signal from a sample to a 
known concentration o f nanoparticles. Similar technique can be applied using a UV/ Vis
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spectrometer by correlating the absorbance with the concentration. Recently, a novel 
device that uses multi-wavelength pulse plethysmograph. based on Beer-Lamberf s Law 
o f highly scattering medium, was designed to determine the optical density o f a pulsating 
medium was successfully implemented to find the concentration o f gold nanoshells in 
vivo in murine models [43], This device uses off-the-shelf optoelectronic components in 
conjunction with a tailor-made LABVIFW  VI with an algorithm based on Beer- 
Lamberf s Law and pulse oximetry theory to calculate real time optical density o f 
nanoparticles in the blood. Currently, this device is able to measure the optical density o f 
particles that are absorbent at the near infra-red band o f the spectrum [44J. This prototype 
is able to work with various therapeutic particles to track the concentration o f in vivo gold 
nanoparticles in real time.
This research plan utilizes gold nanoshells as currently used in clinical 
investigations in the United States (Investigational Device Exemption 070090) and 
spectrally similar gold nanorods, and other optically active therapeutic agents. The 
objective o f this work w ill be the application o f pulse plethysmographic system for a 
broad-based pre-clinical and clinical use toward the control o f intravenous drugs into the 
target sites. In the context o f nanoparticles, the relationships between the variations in 
therapeutic dose and treatment efficacy have not been firm ly established in the literature. 
This project w ill also help develop a pharmacokinetic population model which could be 
used to predict accumulation for selected doses and injection patterns based on a larger 
data set [45]. Working with the assumption that increased circulation and AUC are major 
contributing factors that influence tumor uptake, this project w ill investigate the effect o f 
compounds that suppress RES function when used in conjunction with nanoparticle
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injections. Working towards improvement o f clinical impact o f nanoparticle therapy, this 
project w ill develop a method o f rapid analysis o f tumor particles to assess accumulation 
within a clinically relevant time frame. In addition, this research aims to expand the 
application o f the photo plethysmograph into real-time sensing o f circulation o f other 
optically active molecular drugs.
In addition to assessing the effect o f AUC on tumor uptake, this research w ill aim 
to increase the efficacy o f nanoparticle based therapy by increasing the in vivo circulation 
half-life, thus providing a longer exposure time o f the therapeutic nanoparticles. Since the 
Kupffer cells o f the liver provide a major removal route o f nanoparticles by the RES, an 
effective RES blocking agent should enable longer circulation o f the nanoparticles in 
vivo. This research aims to demonstrate the use o f X-Carrageenan (linear sulphated 
polysaccharide) to suppress the actions o f the RES, and allow for longer circulation o f 
gold nanoparticles temporarily.
As the research strives towards the determination o f the best clinical and 
physiological parameters for optimum dose delivery, the experiments are designed to 
approach the problem from different areas. This project was started with two major aims 
that would demonstrate the potential benefits o f integrating the pulse photometer with an 
established nanoparticle-based cancer therapy. The aim is to improve treatment 
reproducibility as we precisely control and verify the delivered dose. This objective was 
expanded to encompass other clinically relevant drugs like quinine and amphotericin b, 
by making modifications to the prototype. The results o f each unique experiment were 
used to construct a standard one compartment pharmacokinetic model. The employment 
o f near real-time pharmacokinetics was done to investigate the physical response to
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nanoparticles and other intravenously injected particles, giving us the ability to make 
rapid recommendations on treatments. In accordance with the purpose o f clinically 
relevant feedback, an EDXRF elemental analysis protocol was developed to quantify the 
accumulation o f therapeutic gold nanoparticles in target tissue in a clinically relevant 
time frame.
The body o f research presented in this dissertation is the product o f iterative and 
improvements to develop protocols rapidly for use in translational pre-clinical trials using 
gold nanorods. The work started with the purpose o f the implementation o f the novel 
pulse photometer in a clinical setting in order to help health care providers make 
informed decisions based on rapid feedback on nanoparticle treatment. In order to 
achieve that goal, proper calibration with existing standards and establishing the working 
range o f the pulse photometer was required (as described in Chapter 3: Calibration and 
Determination o f Operational Range o f the Pulse Photometer).
After implementation o f the pulse photometer, the focus o f the research was to 
assess the efficacy o f the treatment in terms o f some quantifiable metric, which in this 
case was the final accumulation o f the gold nanoparticles in the tumor. Based on the 
premise that real time knowledge o f bioavailability o f the nanoparticles during the 
injection phase should inform the outcome (i.e. final accumulation in the tumor), 
experiments were conducted to investigate the predictability o f the final accumulation 
based on the bioavailability o f the nanorods, as described in Chapter 4: Use o f Real-Time 
Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods. The initial experiments o f 
0: Use o f Real-Time Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods 
revealed a need to develop a rapid elemental analysis system to be able to observe a full
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set o f data on one animal prior to the beginning o f an experiment on another animal (and 
for future clinical work). This need for a rapid elemental analysis system leads to the 
work in Chapter 4: Development o f an Energy Dispersive X-Ray fluorescence (HDXRF) 
Technique for Elemental Analysis o f Gold Nanorods, and this novel rapid elemental 
analysis technique was used in the revised experiments o f the Chapter 5: Use o f Real- 
Time Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods. The data from these 
experiments was used to investigate the effect o f adjuvant therapies in the circulation o f 
nanorods during the accumulation phase. Exploring this possibility led to application o f 
reticuloendothelial system (RES) blocking agent to achieve longer circulation times, 
which is described in Chapter 6: Reticuloendothelial System Blockade and Redosing o f 
Gold Nanorods in a Murine Model. In addition, the possibility o f expanding the 
application o f the novel pulse photometer in in vivo sensing o f other clinically relevant 
molecular drugs (quinine and amphotericin b) was explored, the details o f which are 
described in Chapter 7 and Chapter 8, respectively.
The objective o f this research is to facilitate improvement in clinical outcomes 
with the use o f real time data to inform point o f care decisions. The rationale o f these 
studies was to demonstrate that dose verification, population pharmacokinetic modeling, 
and protocol modifications w ill be instrumental in informing clinical decisions, which 
then w ill improve efficacy o f any treatment. Using tools such as pulse plethysmography 
instrumentation for dose verification and drug sensing, and EDXRF for rapid 
quantification for population modeling, efforts can be made to address variability among 
individuals, and increase reproducibility in treatment outcomes.
CHAPTER 2
LITERATURE REVIEW
As the nanoparticles were ready for therapeutic use in the clinic, the need for their 
real time monitoring was realized. The need for instrumentation for the real time sensing 
and the development o f the pulse photometer, which was useful in determining the real 
time bioavailability o f the nanoparticles. In addition, a pharmacokinetic model was 
needed to establish a relationship between different pharmacokinetic variables and final 
accumulation in the target organs (tumor). The data required to establish such a model 
needed a method o f elemental analysis o f gold in the tumors, which was achieved by 
developing a new EDXRF protocol for analysis o f gold in the tissue. This chapter 
provides some background on the current state and the research needed on the therapeutic 
nanoparticles, their clearance from the body, and the development o f pulse photometer 
for real time monitoring o f nanoparticles in the body, and the development o f a new 
EDXRF protocol for analysis o f gold in the tissue for use in development o f a population 
pharmacokinetic model.
2.1 Gold Nanoparticles
The gold nanoparticles (nanoshells and nanorods) discussed in this dissertation 
were provided by Nanospectra Biosciences, Inc. (NB1). Their nanoshells are currently in 
pre-clinical and clinical trials under an investigational device exemption (IDE). These
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nanoparticles do not chemically interact with the body and are therefore classified as 
devices instead o f drugs. The nanoshells are approximately 150 nm in diameter with a 
mPEG coating, stored in an iso-osmotic solution o f 10% trehalose, and produced in the 
manner described by Oldenberg et al. [46], [47], Biodistribution o f these gold nanoshells 
has been previously conducted where James et al. demonstrated that at 24 hours, the gold 
was primarily accumulated in the organs o f the RES [47],
The gold nanorods provided by NB1 are approximately 15 x 45 nm, PEGylated, 
and suspended in an iso-osmotic solution o f 10% trehalose. The nanorods are synthesized 
using a modified version o f the method developed by Jana et al. [48], Biodistribution o f 
these gold nanorods has been conducted. Goodrich el al. demonstrated the primary 
accumulation o f gold after 24 hours was in the organs o f the RES (liver approximately 
77% o f injected dose and spleen approximately 6% o f injected dose) [36], Optical 
coherence tomography was used to monitor the accumulation and dissipation in 
mammary tumors PEGylated gold nanorods o f similar size, the maximum accumulation 
was found to be at 16 hours [49].
2.2 Clearance of Gold Nanoshells and Nanorods
Nanoparticles, when circulating in vivo, are subject to rapid opsonization. The 
Kupffer cells (tissue macrophages o f the liver) are unable to detect foreign bodies in the 
blood directly, so this process requires the opsonization o f the nanoparticles while they 
are circulating. This opsonization is followed by removal from the blood by macrophages 
o f the reticuloendothelial system (RES) within seconds o f injection. This rapid clearance 
causes very short half-lives, which is incompatible with passive targeting [50], [51]. This 
problem is avoided by coating the nanoparticles with chemicals such as poly ethylene
20
glycol (PEG) to “ stealth" them from the immune system effectively until they have 
reached their target.
Charged and metal particles are more rapidly and efficiently cleared by the RES 
compared to electrically neutral particles. This fast clearance created a need to make the 
particles electrically neutral or hide the particles by adding a surface coating [31 ]. 
Masking nanoparticles from the RES is necessary to increase the circulation time to a 
period long enough for passive accumulation, which led to the application o f nanoparticle 
coatings to mask the nanoparticles from the immune system. The most common surface 
coating for stealth nanoparticles is polyethylene glycol (PEG). PEG uses steric hindrance 
to prevent the adsorption o f opsonins and delaying the uptake by phagocytic cells. 
PEGylation o f nanoparticles is a common method o f evasion o f the immune system and 
used in liposomes, polymeric nanoparticles, and gold nanoparticles. A form o f PEG 
(DSPE-PEG) has been used to suppress opsonizing proteins, and chol-PEG or PE-PEG 
has shown a concentration dependent ability to inhibit binding o f nanoparticles with 
immunoglobulins, and almost eliminate the binding at large concentrations [51],
2.3 Pulse Photometer
Optical methods have recently been explored as a method for monitoring the in 
vivo activities o f gold nanoparticles [52-54]. This is made possible because the energy 
most attenuated by these nanoparticles resides in the region o f wavelengths (700-1100 
nm) known as the tissue optical window. It is in this band that hemoglobin, a primary 
absorber in vascular tissue, along with melanin and water, demonstrate extinction minima 
and thus in vivo penetration depth is maximal. The spectral analysis o f arterial blood has 
been employed in applications like photoacoustic tomography [55] oximetry [56],
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glucosimetry [57], and pulse dye densitometry [58-61]. These methods isolate the time- 
varying attenuation o f light resulting from the arterial pulsation o f each heartbeat.
A photodetector circuit is used to detect the amount o f transmitted light at 
selected wavelengths by converting it to a time varying electrical signal. This signal is a 
waveform referred to as a photoplethysmogram (PPG) which consists o f a time varying 
portion (AC) and baseline (DC). The magnitude o f the AC signal is the envelope o f the 
PPG and the magnitude o f the DC portion is the average value o f the PPG.
This allows for an analysis o f the isolated optical properties o f arterial blood, 
which change, often drastically, with the addition o f optically attenuating agents. Pulse 
dye densitometry exploits the same phenomena to measure the concentration o f a dye 
injected into the vasculature suggesting that similar techniques could be applied to the 
monitoring o f optically extinguishing nanoparticles. The measurement o f optically 
attenuating species in the blood can be done by employing the Beer-Lambert Taw at 
several wavelengths.
By examining the ratio o f the changes in attenuation o f light at these wavelengths, 
the calculations become path-length independent. This suggests, in theory, that the 
measurements are also independent o f anatomical probing location as long as a suitable 
pulsatile signal is obtained. In pulse oximetry, for example, the ratio o f pulsatile changes 
at a red (X.1) and infrared wavelength (X2) is used to determine the percent oxygen 
saturation (Sp02) in arterial blood. These measurements can be made on several 
anatomical locations including the fingers, toes, earlobes, and noses with little difference 
in the measured oxygen saturation.
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The ratio o f these pulsatile changes can be determined using the DC and AC 
portions o f the PPG, which can be equated to small changes in attenuation o f light 
referred to as R [62]. The setup o f the instrumentation, the individual channels and the 
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Figure 2-1: A schematic o f the circuitry and software interface o f the pulse photometer. 
Channels 1, 3 and 5 carry the information for the three wavelengths, and channel 7 is not 
used; “ sub” is the background subtraction channel. “ LPF”  represents low pass filters with 
a cutoff o f 29 Hz.
These wavelengths are selected to correspond to the extinction properties o f gold 
nanoshells. The device (shown in Figure 2-1) consists o f a probe compatible with mouse 
anatomy, analog circuitry, a data acquisition card, and LabVlEW software [43J.
The probe includes an LED that emits at four unique wavelengths (660, 735, 805, 
and 940). This LED is purchased through Marubeni out o f Santa Clara, California. Only 
the 805 and 940 nm wavelengths are used in the probe. A photodiode (Hamamatsu 
Hamamatsu City, Japan) is used on the other side o f the subject to record the changes in 
emitted light through the subject. The additional analog circuitry consists o f filtering and 
timing systems and LED drivers.
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The addition o f multiple wavelengths to analyze several ratios can be used to 
determine the concentrations o f several optically attenuating species in the arterial blood 
|64]. [65], This multi-wavelength technique has recently been employed in the 
improvement o f the pulse oximeter to account for the contribution o f pulsatile tissue, 
venous blood, dyshemoglobins, and total hemoglobin concentration 165. 66],
The multispectral pulse photometer is commonly used for mice under light 
anesthesia or no anesthesia to detect the intravascular concentration o f nanorods. The 
pulse photometer helps by providing the levels o f the nanoshells or nanorods in the 
vasculature displayed as optical density. The pulse photometer does this by observing 
pulsatile changes in optical extinction between 805 and 940 nm, and calculating a ratio 
between the wavelengths known as R shown in Eq. 2-1, where VAc is the alternating 
current voltage, VDC is the direct current voltage, Aj is wavelength 1. and A2 is 
wavelength 2:
The pulse photometer then simultaneously solves Eq. 2-2 and Eq. 2-3 to solve for 
the optical density o f the nanorods (ODNR), which corresponds the the absorption caused 
by the nanorods in solution and is concentration dependent, and oxygen saturation (S) 
both in real time using LabVIEW, using the R (which is the ratiometric value 
representing the ratio o f the absorptions at the wavelengths used, which, in the example 
demonstrated are 805 nm and 940 nm) values, effective attenuation coefficients o f 
oxygenated whole blood (p^bQl) at the wavelength o f interrogation (A), and effective
Eq. 2-1
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attenuation coefficients o f deoxygenated whole blood (pj'lbr) at wavelength o f 
interrogation (A) which can be shown as
D _ s(̂ Hhc)3) f f1 ~ŝ (nMb, )+mnr 805 Eq. 2-2
*'805/940 940 V /, ,n/ 9401,
V  Hb(b j *■ ) |lNR 940
and
_ s( C ) 2)+̂ -s>(M!ig)^NRh6o Eq-2-3
*'660/940 940 Vn 940V
V̂lTlb( >2 / v Hbf ) N̂R 940
The use o f the pulse photometer allows us to obtain as many data points on the 
blood plasma concentration curve as needed, thus eliminating the need o f blood draws for 
those estimations. This ability to obtain as many data points as desired is advantageous so 
we build a more reliable blood plasma concentration curve. Another main advantage o f 
the pulse photometer is the potential for use in near real-time applications o f 
pharmacokinetic models and feedback controls during nanoparticle infusion.
2.4 Pharmacokinetics
Pharmacokinetics is the quantitative study o f a drug or a therapeutic particle after 
it has been introduced into the body until its complete elimination [67]. The 
pharmacokinetics o f the nanoparticles is important because the knowledge about their 
biodistribution o f nanorods informs the outcome o f the nanoparticle therapy. Starting with 
the most basic o f pharmacokinetic models, this section discusses two basic models, the one 
compartment and population pharmacokinetic models.
Physiologically based pharmacokinetic models typically include significantly more 
compartments to account for more biological systems. De Jong et al. conducted 
biodistribution studies, and demonstrated a presence o f gold nanoparticles (o f multiple
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sizes) in the blood, liver, spleen, lung, brain, heart, and kidney at 24 hours 168). The 
pharmacokinetic systems are divided into different compartments for simplicity o f 
modeling, which is typically later verified empirically by animal experimentation. The 
simple compartmental models we use in this study is one compartmental model, which is 
described as follows.
2.4.1 One Compartment Model
A one compartment non-physiological based model, is currently being used due to 
the availability o f data. The one compartment model for the experimental data would 
represent the blood volume o f the mouse. Concentration o f nanoparticles in the blood 
volume o f the mouse is available in the form o f experimental data.
The model uses Eq. 2-4 to give a concentration as a function o f time, which can be 
used to describe several clinical variables related to the injection. A conceptual schematic 
o f the one compartmental model can be seen in Figure 2-2.
Nanoparticle Injection
Compartment One 
Volum e = V  
Concentration =  C
Clearance (K*)
Figure 2-2: Schematic demonstrating one compartment model.
C=C0e'kct, Eq. 2-4
where C is the concentration, CQ is the initial concentration. ke is the elimination rate 
constant, and t  is time.
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where D is the initial dose and VOD the volume o f distribution. Using this basic model, the
half-life (U) is calculated using Eq. 2-6:
ln(2) 0.693 t| = —  = —
5 K  K
Eq. 2-6
This model demonstrates the removal o f the nanoparticles from the blood as a 
function o f time, which is defined as a single exponential decay model. This model does 
not account for differences in the accumulation or release o f nanoparticles from tissues, 
but only the removal o f the nanoparticles from the blood. Other models, such as the two 
compartment physiological models, would provide a better model o f the movement o f 
nanoparticles. These models would depend on the availability o f real-time data reflecting 
accumulation in target tissues.
2.4.2 Population Pharmacokinetics
Population pharmacokinetics investigates the variability between patients (or 
subjects) given the same treatment, also referred to as inter-patient (or subject) 
variability. The objective o f population pharmacokinetics is to account for the inter­
subject variability in terms o f subject specific variables such as age, sex, or weight. The 
developed population pharmacokinetics analysis techniques are very valuable in analysis 
o f studies with scarce data. The availability o f sparse data in pharmacokinetics led to the 
development o f several analysis techniques such as nonlinear mixed effects modeling, 
non-parametric maximum likelihood, and Bayesian modeling. These techniques are 
useful where traditional methods o f analyses, which require large data sets, are not.
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Nonlinear mixed effects modeling is the most popular method, due in part to the software 
package NONMEM [69J. Models generated through population pharmacokinetics to 
have the ability to reveal sub-group specific effects, and covariate effects that can help 
the clinicians make decisions about the treatment process.
2.5 Elemental Analysis
The application o f elemental analysis in nanomedicine stems from the need for 
feedback to judge the efficacy o f the treatment. Different types o f metal nanoparticles are 
employed in nanomedicine for various applications. For example, gold nanoparticles are 
being used in animal and human trials for assessing the feasibility o f photothermal 
ablation o f inoperable solid tumors [28], [30], A potential way to enhance efficacy in 
such cancer therapies is to increase feedback through additional clinical signs during the 
accumulation and treatment phases. Concurrently, innovative medical devices are being 
developed to provide near-instantaneous pharmacokinetic feedback. [35], [36] suggesting 
the need for an elemental analysis technique that provides similarly rapid quantitative 
feedback o f biodistribution. These analyses could assess when, and to what degree, the 
particles were accumulating in the tumor, or i f  they were being eliminated by the RES. 
The use o f rapid elemental analysis coupled with real-time pharmacokinetic 
measurements could help predict the most appropriate time for animal or human ablation 
(e.g. photothermal) o f the tumor. For animal studies, a faster technique can have a major 
impact for companies involved in nanomaterial quality control and product development. 
For human trials, the ability to measure, or predict, the accumulation o f the nanoparticles 
in the target tissues could improve treatment outcomes for some o f the approximately 
52,000 anticipated deaths due to cancers targeted by this therapy each year in the United
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States [9], Biodistribution o f gold nanorods is normally analyzed through inductively 
coupled plasma mass spectrometry (ICP-MS) or instrumental neutron activation analysis 
(INAA) [47], ICP-MS requires elaborate and time-consuming sample preparation (up to 
104 hours) [70]. INAA does not require a long sample digestion and preparation, but 
requires longer analysis [47]. Although both o f these techniques are accurate, they take 
from days to weeks to get results, longer than a clinical treatment time o f one day. I f  the 
data were available within the clinical treatment time, we hypothesize that some accuracy 
could be sacrificed compared to these standard methods.
Energy Dispersive X-Ray Fluorescence (EDXRF) is a technique used for bulk 
and ppm elemental analysis that is rapid, robust and requires little sample preparation 
time [71], EDXRF has been previously used for quantitative in vivo and ex vivo analysis 
o f gold in tissues like kidney and liver [72], [73], Previous work with biological samples 
demonstrates the need for thin samples, so that matrix effects can be neglected [74], 
Common EDXRF protocols require a long process o f drying, crushing, and pressing 
samples into pellets [74], [75]. Based on guidance from the literature towards optimizing 
a rapid sample preparation, the key aspects o f this protocol include: sample thickness, 
geometry, and homogeneity [74],
Chapter 4 outlines the procedure developed for a benchtop EDXRF elemental 
gold analysis o f gold nanorods (~ 15 x 45 nm), an optically absorptive cylindrical nano­
object used in nanomedicine. The protocol presented includes tissue 
digestion/homogenization in potassium hydroxide followed by desiccation in the sample 
cup before EDXRF analysis. Using subcutaneous mouse tumors, the elemental analysis 
was completed in less than 12 hours from the time o f tissue collection.
CHAPTER 3
CALIBRATION AND DETERMINATION OF 
OPERATIONAL RANGE OF THE 
PULSE PHOTOMETER
This section discusses the experiments dealing with establishing the operating 
dynamic range o f an optoelectronic device designed to measure the concentration o f 
optically resonant nanoparticles in vivo. Gold nanoparticles (nanorods and nanoshells) are 
a class o f optically resonant nanoparticles that are used for photo-thermal ablation (PTA) 
o f tumors. PTA is a cancer treatment modality using preferential heating o f tumor tissue 
to the point o f irreversible cell damage by illumination with a light source. NIR 
extinguishing gold nanoparticles can be used in PTA to enhance absorption and localized 
heating in tissues where they collect. In the treatment o f tumors, nanoparticles can be 
injected in the vasculature and extravagate at the tumor site. Once optimal nanoparticles 
collection is achieved, a laser emitting a wavelength corresponding to its resonant 
wavelength is used to irradiate the tumor. The absorption o f this energy causes a 
localized significant increase in temperature, causing damage to the cells in the tumor but 
leaving tissues not containing NS unaffected. The development o f a novel optoelectronic 




The optoelectronic instrumentation is based on the pulse oximetry theory, which 
itself was based on pulse plethysmography. Pulse plethysmography is an optical 
technique that observes the changes in pulsatile tissue to measure the oxygen saturation 
level (SPO2). Aoyagi discovered that i f  the signal from pulsating arterial blood was 
analyzed, the attenuating factors could be subtracted [63 j. Since the pulse oximeter uses 
changes in the attenuation coefficient o f blood to calculate the concentration o f oxygen in 
pulsatile blood, the same principle was applied to calculate the concentration o f optically 
resonant gold nanoparticles in the blood, since they too, change the attenuation o f visible 
light in blood.
Once the instrumentation was complete and the experiments were performed 
using the pulse photometer, the data obtained from it was in terms o f optical density, 
which is the measure o f the attenuation o f light in the medium. The readings were 
verified by conducting blood draws with each data point. The blood samples were 
analyzed using UV/Vis spectrometry, which revealed a linear correlation between the 
readings o f the device and UV/Vis spectrometer. (R2 = 0.9839, p-value = 2.2X10'16) [43]
However, the question o f limits o f operation o f the pulse photometer still 
remained. Therefore, the following experiments were designed to determine the upper 
and lower dynamic o f the pulse photometer.
3.1 Upper Dynamic Range Experiments
The experiment to determine the upper detectable lim it o f optical density values 
by the pulse photometer was performed. The experiment was set up in such a way that a 
nai ve balb/C mouse was injected in three minute successions o f a 20 pL volumes, and a 
continuous pulse photometer reading was taken until the readings were inconsistent
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(caused by the assumed saturation o f the detector photodiode, where too little light is 
being passed through the tissue for the detector to detect).
3.2 Materials and Methods
3.2.1 Animal Experiments
A ll experiments were conducted using BALB/c female (n = 3). A ll animals were 
handled and cared for in accordance with the Louisiana Tech University and Nanospectra 
Biosciences, Inc. (NBI, Houston, TX) Institutional Animal Care and Use Committees.
3.2.2 Temperature Control
Prior to injection and for three and a half hours after injection the animal was kept 
under specific temperature control (35-39°C), to facilitate intravenous cannulation and to 
normalize the extravasation o f the gold nanorods [33].
3.2.3 Dosaue
For this experiment, the animals received 300 optical density gold nanoshells in 
steps o f 25 pL approximately five minutes apart. Since the objective o f the experiment 
was to establish the upper lim it o f detection o f the pulse photometer, the total injection 
supplied about 100 pL o f 300 OD solution o f nanoshells (3-4 times the normal dose).
3.2.4 Anesthesia
Isoflurane inhalation (3% for induction and 2% for maintenance) anesthesia was 
used to immobilize the animal for injection and to assist with the collection o f the first
PPG reading. The flow rate was maintained at 1.5 L/min.
32
3.2.5 Injection
Nanoshell injections were administered via intravenous cannulation o f the tail 
vein, using a 28 GA needle. The injections were given at a rate o f 9-18 pL/minute 
depending on dose volume and expected remaining time under anesthesia.
The data thus obtained was imported in M ATLAB® and it was plotted in a 
weighed scale, using the 'loess’ curve smoothing function (described in Appendix G). 
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Figure 3-1: The bioavailability curve o f a naive BALB/c mouse (first injection at around 
18 mins, and an injection every five minutes. The graphed data represents the data with 
artifacts removed (using M ATLAB code). The average o f upper lim it o f detection o f the 
device was found to be 7.94 optical density (n = 3).
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After that the ‘ trapz’ function in M ATLAB was used to calculate the area 
under the curve o f the original data and that was compared to the area under the curve o f 
the smoothed data.
3.2.6 Example Calculation
The following is the theory behind the calculations that were used to compute the 
signal to noise ratio used in calculating the upper lim it o f detection.Let's assume that x is 
a data point from the original curve at time t and x ’ is the data point from the smooth 
curve at the same time t.
Now, normalized Area under the curve (NAUC) for original data point from the 
discrete data series is defined by the following equation:
/dx2dt’ E<i- 3-1
Where normalized area under the curve (NAUC) for the smooth data obtained 
from the smoothing function is defined by the following equation:
Jo W d t, Eq. 3-2
and the difference between the two is caused by the noise in the signal.
So, the signal to noise ratio calculated from the NAUC o f the noise and NAUC o f 
the smoothed signal by using the formula:
SNR-20 log ( ^ ) ,  Eq. 3-3
where A i is the NAUC o f the noise and Ao is the NAUC o f the original data.
To better analyze the appropriate lim it o f the pulse photometer, the whole data 
was divided into segments for each injection and the SNR o f those groups was compared.
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The highest OD levels at which the pulse photometer data maintained a SNR o f 
20 while fu lfilling all the other requirements o f good data (ie. 10 mV AC voltage peak-to- 
peak, the standard deviation below 0.03) is considered the upper lim it o f detection o f 
pulse photometer.
3.2.7 Discussion
The upper lim it o f detection o f the pulse photometer at 805 nm was determined to 
be 7.94 OD. Cope et al. established that an optical density o f 10 translates to 8-9 cm of 
brain tissue [76J. Near infra-red light has been used to perform transmission mode 
spectrometry to monitor cerebral oxygenation o f a larger volume o f tissue (intact head o f 
a cat, preterm infants) in the past [76, 77], Although time resolved spectroscopy is 
required to determine the exact path length and the differential path length factor (DPF) 
o f photons in the tissue, this ability to detect approximately eight optical density in the 
near infra range points to the fact that this prototype can be used for studies in larger 
animals. This is confirmed by the presence o f pulsatile signals received by the detector 
through the tissue at those high concentrations.
However, it is important to note that an optical density o f eight has an implicit 
unit o f cm'1 associated with it. Since these experiments are performed in a mouse tail, the 
trans illumination distance is not the standardized 1 cm path length. Moreover, the signal 
analyzed by the pulse photometer only accounts for the AC portion o f the signal, which is 
the pulsatile arterial blood (as shown in Figure 1-1). This means that the optical density 
o f eight as read by the pulse photometer describes the absorption equivalent to 1 cm 
cuvette filled with the arterial blood.
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In addition, the specifications o f the parts used in the prototype can be a helpful 
guide in a rough estimation o f the upper lim it o f detection. The noise equivalent power 
and the output irradiance o f the LED used can be used to roughly estimate the upper lim it 
o f detection for any given detector/LED combination for a particular wavelength. This 
would be helpful in quick estimation o f whether this prototype w ill be suitable for 
detection o f other chemicals with known absorption peaks. An example calculation is 
shown in Appendix B.
3.3 Lower Limit of Detection
The lower detectable lim it o f the pulse photometer was established using a 
statistical technique. Baseline data was collected from 18 BALB/c mice and compiled to 
form a probability distribution around the baseline value.
BALB/c mice were repeatedly injected with very low dosage o f gold nanoshells, 
and the data was compiled into an input matrix. Then, M ATLAB was used to find the 
nearest probability distribution within the data that was outside the 95.3% confidence 
interval o f the baseline distribution. The M ATLAB algorithm was designed to maximize 
the Bhattacharya Distance Measure (BDM) [75], while minimizing the distance between 
the two means. The computation yielded a mean o f 0.57 OD with a normal distribution 
around the mean, which was classified as the lower range o f detection.
CHAPTER 4
DEVELOPMENT OF AN ENERGY DISPERSIVE 
X-RAY FLUORESCENCE (EDXRF) 
TECHNIQUE FOR ELEMENTAL 
ANALYSIS OF GOLD 
NANORODS
4.1 Introduction and Specifications
This chapter outlines the procedure developed for a benchtop EDXRF elemental 
gold analysis o f gold nanorods (~ 15 x 45 nm), an optically absoiptive cylindrical nano­
object used in nanomedicine. The protocol presented in this report includes tissue 
digestion/homogenization in potassium hydroxide followed by desiccation in the sample 
cup before EDXRF analysis. Using subcutaneous mouse tumors, the elemental analysis 
was completed in less than 12 hours from the time o f tissue collection.
This device uses x-ray excitation o f a sample to characterize the elemental 
composition. The specifications for the development o f this elemental analysis protocol 
are:
•  Complete sample analysis 12 hours after collection.
•  Minimal sample preparation.
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4.2 Materials and Methods
4.2.1 Animal Experiments
A ll experiments were conducted using BALB/c female mice inoculated with 
CT26.WT tumors on the subcutaneous flank. The accumulation experiment was 
performed on animals with a target tumor size o f greater than 5 mm in length and width. 
A ll animals were handled and cared for in accordance with the Louisiana Tech University 
and Nanospectra Biosciences, Inc. (NBI, Houston. TX) Institutional Animal Care and 
Use Committees.
4.2.2 Temperature Control
Prior to injection and for three and a half hours after injection the animal was kept 
under specific temperature control (35-39°C) to facilitate intravenous cannulation and to 
normalize the extravasation o f the gold nanorods [37],
4.2.3 Dose Groups
For this experiment, two dose groups were used. Both o f the groups were based 
on the multiples o f standard dose administered by NBI. The first group received 4.5 pL/g 
subject weight o f 100 optical density gold nanorods (Dose group A) and the second group 
received 9 pL/g o f 100 optical density gold nanorods (Dose group B).
4.2.4 Anesthesia
For this experiment we used 2,2,2-Tribromoethanol (Sigma-Aldrich T48402)
mixed with 2-Methyl-2-Butanol (A lfa Aesar A 18304), more commonly referred to as 
Avertin, administered via intraperitoneal (IP) injection. The working solution o f Avertin 
was administered at 30 pL o f solution per gram body weight. Booster injections (0.5x) 
were delivered as necessary.
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4.2.5 Injection
Nanorod injections were administered via intravenous cannulation o f the tail vein, 
using a 28 GA needle. The injections were given at a rate o f 9-18 pE/minute depending 
on dose volume and expected remaining time under anesthesia.
4.2.6 End o f Experiment and Organ Collection
At the end o f the experiment, defined as when the blood plasma concentration o f 
circulating nanorods reached one optical density, a 20 pL IP injection o f a 
Ketamine/Xylazane mix was administered as heavy anesthesia. A dissection was started 
from the base o f the abdominal cavity to sacrifice the animal by exsanguination via 
cardiac puncture using a 22 GA needle/syringe prefilled with 100 pL o f heparin. After 
animal sacrifice, the following tissues were collected for further study: heart, lungs, liver, 
kidneys, spleen, and tumor.
4.2.7 EDXRF Sample Preparation
A wet weight o f the tissue was obtained at the time o f extraction. A 20% w/w 
KOH solution was added to the tissue based on the sample weight (3 pL/mg). The tissue 
and base solution were placed in a shaker or rocker until the tissue liquefied, 
approximately four to six hours. Aliquots o f 35 pL (selected to cover our area o f 
detection: 15 mm x 12 mm, containing approximately 0.04 g o f tumor tissue) were placed 
in EDXRF sample cups on a Prolene® thin film  support (Chemplex Industries Inc., 4pm 
thick. Cat. # 3017). The tissue solution was then dried in the sample cup for two hours in 
a vacuum oven at 30°C under 15 in Hg vacuum to reduce the movement o f the sample. 
The samples were analyzed in an ARL Quant’X (Thermo Scientific) EDXRF 
spectrometer (4-50 KV X-ray generator, Beryllium window, with 80°geometry between
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x-ray tube, sample, and detector) using a thick Palladium (liter (Mid-Zc range) for two 
minutes (50% dead time). Three replicates were prepared from most tissue samples. Each 
sample cup was scanned ten times which produced up to 30 spectra for each tumor. The 
spinner was turned on during each scan to minimize the error from the sample placement
Each spectrum was analyzed to compute the calibration curve shown in for a 
range o f gold concentrations in the tissue. From the spectra, as shown in Figure 4-1, two 
regions o f interests (ROI) were chosen. From the spectra, as shown in Figure 4-1, two 
regions o f interests (ROI) were chosen. The ROI 1 represents the region for the Lai 
peaks for gold (9.712 KeV). However, that region lies very close to the Kpi peak for zinc 
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Figure 4-1: A raw spectrum o f a sample from the calibration set (PPM value = 
21.73). Vertical lines from left to right: Zn K a' line (8.631 Kev), Zn Kp1 line 
(9.572 Kev), Au L«' line (9.711 Kev), Au Lp'line (11.439 Kev), Br K„' line 
(11.907 Kev). These lines contribute to counts at each given energy.
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The zinc found in the sample is attributed to zinc/aluminum alloy used in the 
sample chamber lid [17-18]. The data (in counts) was normalized in terms o f tube current 
(counts/mA), and the normalized background was subtracted from all the data points.
A standard value o f counts for zinc (obtained from the repeated runs o f 0 ppm) 
sample was then subtracted from all the samples. After the subtraction, the values were 
normalized to obtain the peak intensity values (counts per second/mA). The peak 
intensity values o f the calibration set were plotted against the actual concentration (o f 
standard gold solution in the tissue) to produce a calibration curve.
4.3 Results
The doped tumor samples were plotted and fit with a linear trend line (where 
PPM is the calculated sample concentration in parts per million and PI is the peak 
intensity in counts per second per milliamp) for use as a calibration curve for this 
analysis.
PI = 0.0729*PPM + 0.0174. Eq. 4-1
The calibration curve showed a strong linear correlation (R2 = 0.98) between the 
concentrations o f gold in doped samples (the samples were doped at regular 
concentration in the 0-60 ppm range) with the calculated peak intensity values after the 
manual subtraction. Therefore, this method was deemed suitable for assessment o f gold 
concentration in tumors in the specified concentration range, which was also the 
clinically relevant concentration range for accumulation o f gold nanorods after 
intravenous delivery.
The calibration curve with the doped samples, along with the tumor samples 
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Figure 4-2: EDXRF calibration. This graph demonstrates the raw calibration points (□), 
calibration curve (dashed line), and individual tumors (o).
This method has a detection lim it (3o) o f 1.4 ppm and a sensitivity o f 0.07
cps/mA/PPM.
4.4 Discussion
The EDXRF protocol for gold in the tissue was designed with the following aims: 
quick and easy sample preparation, thin samples, and quantitative results. A 20% KOH 
solution was chosen, after experimentation, to minimize the time for liquefaction o f the 
tissue. Thin sample geometry was implemented because the thick samples were 
impractical given the amount o f tissue available, and to avoid intermediate sample 
thickness. An aliquot o f 35 pL o f tissue was selected to create a thin sample area entirely 
in the detection geometry o f the detector. Quantitative results were obtained using the
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same tissue dilutions and same sample scan time; Using doped tissue samples for 
calibration, we were able to provide a linear relationship between counts and tissue 
concentration. The calibration curve was used to obtain the values o f the concentrations 
(in ppm) for tumor samples (dose group A: n = 8, mean = 10.7 PPM, STDEV = ±5.8 
PPM, and dose group B: n = 9, mean = 25.3, STDEV = ±6.9 PPM). An analysis o f the 
peak intensity (CPS/mA) versus the gold concentration (PPM) using different tissue types 
showed an R2 correlation o f greater than or equal to 0.93, despite having different slopes 
(0.0733-0.0856 cps/mA/PPM).
It was hypothesized that the small variations observed in the reported slopes were 
attributable to variations in tissue densities given that the regressions were similar when 
multiple preparations o f the same tissue type were analyzed. The calculated concentration 
values for gold in the tumors were similar to the work published by Huang el al. which 
used industry standard methods [78], Commercial laboratories that employ INAA or 1CP- 
MS to analyze gold concentration report a detection lim it in the low PPB range. This 
EDXRF analysis method demonstrates a detection lim it o f 1.4 ppm (3c) and a sensitivity 
o f 0.07126 cps/mA/PPM. This higher detection lim it is acceptable due to the clinical 
requirements o f rapid results in the PPM range.
The majority o f the problems encountered were due to the presence o f other 
elements that spectrally overlapped with one or more o f the peaks o f interest, as seen in 
previous work [79]. The zinc KPi peak (9.570 Kev) overlaps the Lai peak for gold (9.712 
Kev). Other peaks were explored for potential use; a second peak, the LP peak (11.204- 
11.914 Kev), for gold overlapped the Kai bromine peak (11.906 Kev). The bromine 
peak was attributed to the use o f avertin (2-2-2-tribromoethanol) as the anesthesia for this
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experiment. The bromine peak was only observed in the tissue samples where avertin was 
used as the anesthesia. For this reason, the use o f anesthesia may influence the elemental 
analysis o f tissues and should be considered among the criteria for selecting anesthesia in 
the experimental design.
4.5 Review of Specifications
A novel EDXRF protocol for rapid analysis o f gold in the tissue, with a sensitivity 
o f 0.07126 cps/mA/PPM and the lower detection lim it o f 1.3 ppm was developed. The 
project met the original specifications demonstrated in Table 4-1. The data from this 
project are included in a publication titled “ Feasibility o f energy dispersive x-ray 
fluorescence determination o f gold in soft tissue for clinical applications”  [80],
Table 4-1: Summary o f Chapter 4 specifications.
Specification
Elemental Analvsis 
Develop a method to rapidly 
quantify the accumulation o f gold 
nanoparticle in the tumor
Develop a protocol for elemental analysis o f 
gold in tumor tissue using EDXRF, sensitive in 
the 0-50 ppm range, rapid enough to inform a 
clinical decision (24-48 hours)
After the development o f the elemental analysis protocol, it was integrated into a 
set o f pre-clinical experiments, with the goal o f development o f a population 
pharmacokinetic model for the gold nanorods. The data from the elemental analysis 
would inform the efficacy o f the treatment (i.e. the final accumulation o f the 
nanoparticles in the tumor) discussed in Chapter 5.
CHAPTER 5
USE OF REAL-TIME PHARMACOKINETICS 
TO PREDICT TUMOR UPTAKE 
OF GOLD NANORODS
5.1 Introduction and Specifications
Nanoparticle directed photothermal ablation o f tumors relies heavily on the 
accumulation o f nanoparticles in the target tissues. An appropriate accumulation o f 
particles is required for proper thermal confinement and ablation o f the target tumor. 
Preclinical studies o f tumor accumulation are being conducted in an effort to predict the 
accumulation o f nanoparticles more accurately. This preclinical study in a murine model 
works to relate the area under the blood plasma concentration curve to uptake and 
retention in the tumor.
The optimization o f treatment variables, such as therapeutic dosage, circulation 
half-life, and clearance rates, is critical in maximizing the efficacy o f a treatment 
modality. Since the nanoparticles are cleared from circulation mostly by the RES, a 
correlation between tumor uptake and retention and bioavailability should exist.
The purpose o f the tumored studies is to correlate standard pharmacokinetic 
metrics to the uptake and retention o f gold nanorods in the tumors. This set o f 
experiments is based a hypothesis that pharmacokinetic metrics w ill be a more accurate 
predictor o f tumor uptake alone and on the specifications outlined as:
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• Blood plasma concentrations w ill be collected in near real-time. After the 
collection, the data can be processed quickly (less than five minutes) after 
collection for inclusion in an actively changing one-compartment 
pharmacokinetic model.
• Population pharmacokinetic models w ill be constructed from the resulting 
data to help study the dynamics o f the gold nanoparticle in vivo after 
intravenous delivery o f the nanoparticles.
• Elemental analysis o f the tumor tissue is completed in under 12 hours post 
experiment, with the outside time lim it o f 24 hours. Additional data 
processing time is limited to one hour after completion o f instrumentation 
time.
This purpose was achieved by using the pulse photometer for the sensing o f the 
plasma concentration o f the nanoparticles in real-time. The ability to measure the 
achieved dose o f nanoparticles in real-time allows us to confirm the delivery to the 
circulatory system in an experimental setting. This study relates the dosage o f 
nanoparticles to the bioavailability curve, which enables a comparison o f the AUC 
relative to a dosage value.
Linear one-compartment (ADVAN1, TRANS2), two-compartment (ADVAN3, 
TRANS4), and three-compartment (AD VAN 11, TRANS4) pharmacokinetic models were 
evaluated using Beysian analysis in NONMEM using the FOCE method. Inter-mouse 
variability random effects were included in the base model and assumed to be log- 




For example, the clearance for the i th mouse can be written in the form o f the 
equation:
CLj=CL , v x e'1' ' , Eq. 5-1
where CLTV is the typical value o f the clearance, and qpL is an independent random 
variable normally distributed about zero that represents the proportional difference
between the clearance in the i th mouse and in the population. Additive, proportional, and
combined residual error structures were tested.
In this study the continuous covariates o f the mouse weight and the categorical 
covariate o f the dose received were tested for potential effects on the pharmacokinetic 
model parameter estimates. The effect o f both the continuous and categorical covariates 
on the typical value o f a parameter was tested using additive, proportional, and 
exponential function forms.
For example, the additive effect o f the dose group variable on the central 
compartment volume o f distribution is:
V l rv= e l+(DOSEi- l )0 2, Eq. 5-2
where Qx and d2 are the estimated fixed effect parameters, DOSE* is either one or two, 
which depends on whether the t th mouse received a x l dose or a x2 dose. For the final 
model, each covariate was tested individually using a forward addition followed by the 
backward elimination method. Model selection was based on the likelihood ration test 
using the NONMEM objective function values (OFV). The OFV equals -2 times the log- 
likelihood (plus a constant) so the difference in OFV between models is approximately 
chi-squared distributed. A difference o f 3.84 is significant at the P = 0.05 level for nested 
models with one degree o f freedom.
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The spectra from a calibration set (o f known concentration values, created using 
tissue and gold standard solution) were extracted and the area under the curve o f the gold 
T-al peak (9,30 to 9.94 KeV) was calculated. From these values, the peak intensities 
were calculated and a calibration curve was established. The calibration curve shown in 
the figure shown has the peak intensity values (cps/mA) against known concentration 
(ppm) values.
5.2 Materials and Methods
A ll o f the studies involve animal work conducted under protocol approved by the 
Louisiana Tech University and Nanospectra Biosciences. Inc. Institutional Animal Care 
and Use Committee (IACUC). A ll tumored studies involve naive BALB/c females 
inoculated with 1.5 X 105 (50 ml injection volume) CT26.WT murine colon carcinoma 
tumor cells (ATCC) were obtained from NBI. When animals arrived at Louisiana Tech 
University Center for Biomedical Engineering and Rehabilitation sciences, the mice were 
kept in general animal housing until the tumors were at the proper experimental size, 
approximately 100 cubic centimeters.
5.2.1 Experimental Design
This experiment involved seventeen tumor inoculated BALB/c female mice. The 
mice were divided into two dose groups (Group A and Group B) to investigate the 
differences in pharmacokinetic metrics, blood plasma concentration and tumor uptake 
based on the injected dose.
5.2.1.1 Temperature control: The mouse was placed in an environment with an 
ambient temperature o f 35° C for 2.5 hours using a shaking incubator, with the shaker o ff 
(Labnet International, Inc. Edison, NJ. Model #211DS). For at least one hour prior to
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the injection, the ambient temperature was increased to 39° Celsius. During injection and 
while the mice were under anesthesia the temperature was controlled using a heating pad 
(Physitemp Instruments, Inc. Clifton. NJ. Model # TCAT-2LV) and/or a space heater for 
ambient air temperature (Sunbeam Products, Boca Raton, FL. Model # SFH111). After 
the injection, the mouse was returned to the incubator kept in a 39° C environment for the 
first three and a half hours o f the accumulation phase. After the first 3.5 hours, the mouse 
was returned to a room temperature environment for the remainder o f the experiment.
5.2.1.2 Anesthesia and injection: Intravenous cannulation was established after 
the mouse was under anesthesia. Avertin anesthesia was administered by intraperitoneal 
injection at the dosage o f 25 pL/gm body weight, while the air flow was maintained at a 
steady rate o f one L/min with the help o f an Oxygen concentrator (Invacare Model: 
IRC5LX02, Elyria, OF!) during the experiment.
The nanorod injection was done by cannulating one o f the lateral tail veins. Once 
an intravenous cannula has been established and flushed with saline, the pulse 
photometer was attached to the tail. The nanorods were injected at a rate o f up to 18 
micro-liters per minute using a syringe pump (New Era Pump Systems, Inc., Model # 
NE-1010). The — 100 OD nanorods were intravenously injected at the dosage o f 4.5 
pL/gm (Group A) or nine pL/gm (Group B) body weight at the rate o f up to 18 pL/min.
5.2.1.3 Pulse photometer data collection: The pulse photometer was used to read 
the blood plasma concentration o f the nanorods. The pulse photometer was attached to
49
the tail o f the mouse in a warm environment, with the help o f a Physitemp TCAT-2LV 
controller pad set to 38°C and carefully monitored space heaters.
Once temperature stabilization was achieved, the probe was placed on the awake 
animal’s tail and the pulse photometer was allowed to collect data. Five-second averages 
o f the values o f R were computed to assess signal stability. Data collection was designed 
around an assumed six-hour circulation half-life o f the nanorods, and with approximately 
five data points in the first half-life, two in the second and one in the third half-life. Data
collected were as close to the following time points as possible: 5, 45, 120, 240, 360, 450,
720, and 1080 mins.
5.2.1.4 End o f experiment. The mouse was sacrificed when the blood plasma 
concentration reached an optical density o f one plus or minus ten percent. The mouse was 
sedated using a ketamine and zylazine mixture, and then sacrificed by exsanguination via 
cardiac puncture. Liver, kidneys, spleen, tumor, heart, and lungs were collected for 
EDXRF analysis.
5.2.1.5 Data analysis: The collected data was sorted by using a M ATLAB code.
A code was specifically written to extract the data points that meet all the criteria for data 
standards. Anticipating potential transient problems such as motion artifact or low 
perfusion, the signal was deemed acceptable only i f  the following criteria were met:
• AC magnitude was in the range o f 10-100 mV peak-to-peak
• the standard deviation o f R was less than 0.03
•  the heart rate measured on all three channels (660, 805 and 940 nm) were within
ten percent o f each other.
50
The data extracted from the raw experimental data and the average optical density 
value was used to produce a blood plasma concentration curve, which was used to 
calculate the area under the curve (AUC), which was used as a pharmacokinetic 
parameter in the experiment. In addition, the peak value and the half-life o f the clearance 
curve were calculated.
5.2.1.6 EDXRF tumor sample preparation: Using the wet weight o f the tumor, 
obtained the day o f extraction, 20% (m/m) K.OH was added at the rate o f three pL 
KOH/mg o f the tumor. The tissue was left at room temperature in a low speed shaker 
until all tissue dissolved in the solution. From each tumor sample, 30 pL (o f tissue +
KOH solution) was pipetted in up to three unique EDXRF cups.
The solution was then dried down in a vacuum oven at 30°C under 15 in Hg 
vacuum until the tissue sample is completely dry. This process takes about four hours.
The dried samples were run in the EDXRF machine (Quant'X, Thermo Electron 
Corporation) and run each sample with ten replicates. The machine calculated a ppm 
(parts per m illion) value for the concentration o f gold in the tumor.
5.2.1.7 EDXRF tumor sample data analysis: The concentration calculations were 
manually verified by using the calibration set in the machine with the ppm values 
obtained by using the methods. The spectra from the calibration set o f known 
concentration values) were extracted and the area under the curve o f the gold L -a l peak 
(9.94 to 9.30 KeV) was extracted. From these values, the peak intensities were calculated 
and a calibration curve was established using a linear regression model.
The calibration curve compared the peak intensity values (cps/mA) against known 
concentration (ppm) values and was found to be linear within the range o f zero to 60 ppm
gold in tissue, which was deemed to be an appropriate calibration range, based on values 
from literature.
5.3 Results
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Figure 5-1: The graph o f the peak intensity vs. concentration o f gold in tissue for a 
sample o f the Calibration data (A) from Figure 4-1, Experimental group A samples (x, 
n = 8), and Experimental Group B Samples (o, n = 9). The linear correlation (dashed 
line) (y = 0.07126x+0.09984, R2 = 0.93) and 95% prediction interval are shown (solid 
lines).
The half-lives for all mice in the study were computed, and shows the large 
increase in average half-life from 271 minutes in group A to 408 minutes in group B. 
This increase in half-lives is demonstrated in detail for both experimental groups as 
shown in Table 5-1.
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Table 5-1: Half lives for all mice in the study (n = 17). Dose group A got 
9pL/gm, n = 8) and dose group B (4.5 pL/gm, n = 9) with averages and standard 
deviations.
Group A Group B
Mouse 1 320 444
Mouse 2 357 313
Mouse 3 205 523
Mouse 4 267 373
Mouse 5 235 300
Mouse 6 281 356
Mouse 7 268 435
Mouse 8 236 478
Mouse 9 449
A two-compartment model with proportional error best described the nanorod 
population pharmacokinetics. The typical values o f the clearance, inter-compartment 
clearance, and peripheral compartment volume were 5.46 pL/min, 5.82 pL/min, and 
246 pL, respectively (See Table 5-2).
A covariate effect o f nanorod dose on the central volume was found; the 
typical value o f central volume was 1,870 pL in the x l dose group, and 3,100 pL in 
the B dose group. The mouse’s weight did not have a significant effect on any o f the 
pharmacokinetic model parameters. The inter-mouse variability on the clearance.
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central volume, and inter-compartment clearance were 22.5%, 18.8%, and 134.9%, 
respectively. The proportional residual error was 12.6% and the additive error was 
0.00284 pg/pL. The details o f the parameter estimation obtained using the two- 
compartmental model is shown in Table 5-2.






Clearance (pL/min) 5.46(5.5) 22.5 (47.6)
V I (pL) 18.8(38.2)
A dose group 1870(7.7)
B dose group 3100 (20.59)
Q 5.82 (43.6) 134.9 (46.7)
V2 (pL) 246 (33) ---
Proportional error 12.6% (20.3)
Additive Error (pg/pL) 0.00284(132.6)
To investigate the effect o f variables on the accumulation, a single variable 
correlation analysis was performed using the following variables:
AUMC (area under moment curve) (R2 = 0.54), Volume o f distribution (R2 = 
0.08), initial plasma concentration (R2 = 0.36), Dose (R2 = 0.46). Additional 
comparisons evaluated the effects o f injected dose on the AUC (R2 = 0.69), the effect
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o f dose on half-life (R2 = 0.65), and the relationship between half-life and AIJC (R2 
0.64)
The goodness o f fit plots o f the model to the nanorod concentration data 
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Figure 5-2: An example bio distribution curve built from the data taken by the pulse 
photometer.
In addition to the final accumulation in the tumors, various other clinical 
parameters, such as injected dose, peak plasma concentration were compared among 
the two experimental groups. The analysis demonstrated that the tumor weight is the 
only parameter where we are unable to reject the null hypothesis (the means o f the
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dose groups are equal) (a = 0.05). The pertinent p-values and the clinical variables
from the t-tests conducted between the two groups are shown in Table 5-3.
Table 5-3: P-values for comparison o f pharmacokinetic and accumulation 





OD Adjusted Dose 6.24664E-07
injected dose (pL) 5.33305E-08
mean residence time 1.87732E-05
Elimination rate constant 0.00044814
half-life (min) 0.000579249
initial concentration from fit (OD) 0.026590645
Tumor Weight (g) 0.703795196
The data analysis shows an individual correlation between AUC and 
accumulation (ug /gm, or PPM) in the tumor and fitted to a linear regression model, 
which yielded a correlation o f R2 = 0.56.
5.4 Discussion and Review of Specifications
Animals which were included did not show a statistically significant increased 
prediction quality for AUC compared to the dose, suggesting that other yet 
unmeasured or uncontrolled factors play an important role in promoting uptake. In
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the course o f previous related studies, various groups have suggested the need for a 
set o f best practices in terms o f species selection for in vivo experimentation, particle 
size and coating, excipient [81]. In addition, several modeling studies have established 
that physiological variables related to the animal, such as animal blood pressure, core 
and peripheral temperature, and the effect o f anesthesia need to be carefully controlled 
during experimentation, because these parameters seem to have an effect on 
peripheral circulation [15].
Models show that accumulation starts from bioavailability, and few things 
such as perfusion, blood pressure, tumor radius, porosity affect the accumulation.
Good candidates would be any one or more o f the following physiological variables: 
vascularity o f the tumors, pore size o f the vessels in the tumors, local blood pressure 
and necrotic radius o f the tumor. The effect o f tumor interstitial pressure on the 
accumulation o f macromolecules has been investigated theoretically and 
experimentally in the literature [82, 83].
These modeling efforts have identified these factors and suggest that clinical 
protocols, short o f direct control, would be wise to consider the effects o f environment 
and drug interactions on these variables. While the ability to measure the real-time 
concentration o f nanoparticles in the circulating blood brings us one step closer to 
pharmacokinetic modeling o f nanoparticle interactions in the body, the inability to 
quantify variables such as vascularity o f the tumors, and pore size o f the vessels 
around the tumors prevents us from clearly establishing the relationship between the 
variables. AUC has been used as a pharmacokinetic metric to predict therapeutic 
outcome in the past in other drugs [6, 84].
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However, those drugs function by the process o f metabolism in vivo. The 
nanoparticles used in this study are passively accumulated in the tumor by taking the 
advantage o f the leaky vasculature around the tumor tissue. Therefore, we posit that 
the physiological variables such as tumor perfusion, ambient temperature and porosity 
o f the vessels around the tumor play a critical role in the accumulation o f 
nanoparticles in the tumor. The majority o f nanorods are believed to be removed from 
the blood by two pathways; opsonization and elimination by the phagocytes o f the 
reticuloendothelial system (RES), and transient accumulation in other tissues, such as 
solid tumors [85].
The EDXRF protocol used in these experiments enabled us to analyze the 
accumulation data in the tumors in a clinically relevant time frame (24 hours). This 
decrease in sample analysis time made it possible to make adjustments to the 
temperature regulation protocol to improve the accumulation. A direct comparison o f 
the accumulation achieved relative to previous reports was d ifficult without more 
factors for evaluation (e.g. prescribed dose vs. achieved dose, metrics o f circulation, 
peripheral perfusion, etc.); however, it appears that this report, in terms o f percent o f 
dose injected, appeared higher in comparison to other studies we examined in the 
literature [78, 85].
For comparison, Nie et al. reported accumulations between 15 ppm and 75 
ppm but the injected dose was not reported. Puvanakrishnan et al. reported between 
0.118±0.027% ID for nanoshells and 1.35±0.29% ID for nanorods, with a dose o f 7 
pL/g o f 100 OD gold nanoshells and nanorods. AUC is a pharmacometric variable 
that has been previously used in studies to indicate the bioavailability o f a substance
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in the bloodstream [6]. This type o f analysis could be a useful part o f nanoparticle 
manufacturing, in both the prototype and pre-clinical stages, as well as in clinical 
trials. Nanomaterial production schemes are prone to batch-to-batch differences and 
irregularities, and clinical products can suffer from storage stability and contamination 
problems.
These issues along with inherent subject-to-subject variability and the need for 
clinical quality control suggest the utility o f real-time monitoring o f pharmacokinetic 
metrics. The design constraints o f a nanoparticle-based delivery system designed to 
treat a solid tumor, which includes both the specifications o f the nanoparticle in an 
excipient solution and the delivery and treatment protocol, should provide for 
optimization o f accumulation in the tumor.
This optimization is both a function o f bioavailability in the circulation as well 
as providing for circumstances for uptake at the target site. The continuing need for 
best practices in nanomedicine is confounded by the difficulty in relating these 
patient-specific factors to treatment efficacy.
A subset o f this data in an in-progress publication titled “ A Study o f Gold 
Nanorod Bioavailability and Tumor Uptake in a Murine Model." This data was also 
published in a conference proceedings paper titled “ LQR Tracking o f a Delay 
Differential Equation Model for the Study o f Nanoparticle Dosing Strategies for 
Cancer Therapy", in which control strategies to provide an optimal dose, maintain a 
target concentration in the plasma, and the most efficient dose profile, in terms o f the 
amount o f nanoparticles were discussed using a delay differential model, using the
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data obtained from the expreiments discussed in this chapter. [86]. A review o f 
specifications is presented in fable 5-4.
Table 5-4: Review o f specifications.
Specification Status
Address the patient-to- 
patient variability (in terms o f 
dosage, bioavailability, and uptake) 
in therapeutic nanoparticles.
Develop a population model for gold 
nanoparticles to establish a relationship 
between dose, bioavailability and 
accumulation in the tumor.
Dose verification 
Provide real-time 
assessment o f the delivery o f dose 
in gold nanoparticle therapy.
Use o f novel multi-wavelength 
photoplethysmograph for direct dose 




BLOCKADE OF GOLD NANORODS 
IN A MURINE MODEL
6.1 Introduction
Current medical-grade particles are constructed from a variety o f materials 
including lipids, polymers [20], and metals, [22] and are routinely delivered 
intravenously for passive or active accumulation in tumor tissue [21 ]. Accumulation via 
the vascular route increases as the nanoparticle circulation time increases and the 
nanoparticle circulation time increases by discouraging their removal by the 
reticuloendothelial system (RES). The high removal rate observed by the RES o f charged 
and hydrophobic particles, [27] which is a requirement o f a stable colloidal system, 
creates a need to mask the charge by adding a surface coating for nanoparticle therapies 
to be most effective. The Kupffer cells in the liver provide a major removal route o f 
nanoparticles by the RES. Multiple agents have been evaluated to suppress the actions o f 
the Kupffer cells.
Following the investigation outlined in Chapter 5, it was concluded that the AUC 
o f the plasma concentration was one o f the influential factors that affected the final 
accumulation o f the gold nanoparticles in the tumor, ultimately affecting the efficacy
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o f the treatment. Building on this observation, it was hypothesized that the ability to 
modulate the AUC during the clearance phase o f the injection could potentially influence 
the outcome (i.e. the final accumulation) in the tumor. In an effort to modulate the AUC 
during the clearance phase, X-carrageenan was chosen as an adjuvant therapy to be 
administered in conjunction with the nanoparticle, X-carrageenan was chosen because o f 
its ability to cause temporary RES blockade. In addition to its RES suppression ability by 
the suppression o f hepatic phagocytosis, it is also designated as Generally Recognized As 
Safe (GRAS) by the FDA [88] This chapter describes the preliminary experiments that 
established the feasibility o f X-carrageenan as an adjuvant therapy in a pre-clinical 
setting.
6.2 Materials and Methods
6.2.1 Overview
A ll animals were handled and cared for in accordance with the Louisiana Tech 
University Institutional Animal Care and Use Committee. Intravenous injections and 
blood plasma concentrations were monitored using the pulse photometer, and a 
bioavailability curve was created from that data. The purpose o f this pilot study was to 
determine whether X-carrageenan would be an effective RES blockade agent, and also 
determine a dosage plan o f the adjuvant X-carrageenan with the therapeutic particles.
Three BALB/c female mice were assigned one o f three cases (A, B, or C). The 
dosage o f the individual mouse in each case is described as follows:
• Case A was designated to be the initial control group. The mouse was 
injected with a regular dose o f gold nanorods (4.5 pL/gm body wt), and 
the bioavailability curve was recorded with the help o f the pulse
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photometer until complete clearance o f the nanorods. After the clearance 
o f the nanoparticles, the mouse was intravenously injected with 25 mg/kg 
o f 10% X-carrageenan solution, followed by another regular dose o f gold 
nanorods.
• Case B was designed to investigate the efficacy o f X-carrageenan as a RES 
blocking agent after the introduction o f nanorods in circulation. The 
mouse was intravenously injected with a regular dose o f gold nanorods 
(4.5 pL/gm body wt), and the bioavailability curve was recorded with the 
help o f the pulse photometer for the first 30 minutes. After that, the mouse 
was intravenously injected with 25 mg/kg o f 10% X-carrageenan solution, 
and the clearance was measured, using the pulse photometer. The 
objective was to measure any changes in the clearance after the 
introduction o f X-carrageenan in the bloodstream.
• Case C was designed to investigate the efficacy o f X-carrageenan as a RES 
blocking agent before the introduction o f nanorods in circulation. The 
mouse was intravenously injected with 25 mg/kg o f 10% X-carrageenan 
solution, followed by a regular dose o f gold nanorods (4.5 pL/gm body 
wt), and the bioavailability curve was recorded with the help o f the pulse 
photometer.
The real-time concentration o f the nanorods was recorded with the help o f the 
novel pulse photometer, and used to create a bioavailability curve, from which the 
clearance and the half-life o f the nanorods were determined.
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6.2.1.1 Temperature control. The mouse was placed in an environment with an 
ambient temperature o f thirty-five degrees Celsius for two and a half hours using a 
shaking incubator with the shaker o ff (Labnet International, Inc. Edison. NJ. Model #
21 IDS). For at least one hour prior to the injection, the ambient temperature was 
increased to thirty-nine degrees Celsius.
During injection and while the mice were under anesthesia, the temperature was 
controlled using a heating pad (Physitemp Instruments. Inc. Clifton, NJ. Model # TCAT- 
2LV) and/or a space heater for ambient air temperature (Sunbeam Products, Boca Raton, 
FT. Model # SFH111).
After the injection, the mouse was returned to the incubator kept in a 39° C 
environment for the first three and a half hours o f the accumulation phase. After the first 
three and a half hours, the mouse was returned to a room temperature environment for the 
remainder o f the experiment.
6.2.1.2 Anesthesia and injection: Intravenous cannulation was established after 
the mouse was under anesthesia. Isofluorane anesthesia was used at the concentration o f 
3% for induction and 2% for maintenance steady at a rate o f 1.5 L/min with the help o f 
an Oxygen concentrator (Invacare Model: IRC5LX02, Elyria, OH) during the 
experiment.
The nanorod injection was done by cannulating one o f the lateral tail veins. Once 
an intravenous cannula has been established and flushed with saline, the pulse 
photometer was attached to the tail. The nanorods were injected at a rate o f up to 18 
micro-liters per minute using a syringe pump (New Era Pump Systems Inc., Model#NE- 
1010). The — 100 OD nanorods were intravenously injected at the dosage o f 4.5 pL/gm.
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The pulse photometer was used to monitor the condition o f the mouse while under 
anesthesia.
6.2.1.3 Pulse photometer data collection: The pulse photometer was used to read 
the blood plasma concentration o f the nanorods. The Pulse photometer was attached to 
the tail o f the mouse in a warm environment, with the help o f a Physitemp TCAT-2LV 
controller pad set to 38°C and carefully monitored space heaters.
Once temperature stabilization was achieved, the probe was placed on the awake 
animal’s tail and the Pulse photometer was allowed to collect data. Five-second averages 
o f the values o f R were computed to assess signal stability.
6.2.1.4 Data analysis: The collected data was sorted by M ATLAB code. A code 
was specifically written to extract the data points that meet all the criteria for data 
standards. Anticipating potential transient problems such as motion artifact or low 
perfusion, the signal was deemed acceptable only i f  the following criteria were met:
• AC magnitude was in the range o f 10-100 mV peak-to-peak
• the standard deviation o f R was less than 0.03
• The heart rate measured on all three channels (660, 805 and 940 nm) were within
ten percent o f each other.
The data extracted from the raw experimental data and the average optical density 
value was used to produce a blood plasma concentration curve (using a single decay 
exponential model). This curve was used to calculate the clearance, half-lives and area 




It was observed that A.-carrageenan was seen to extend the circulation half-life o f 
the nanorods in all three cases. In the first case (Case A) as shown in Figure 6-1, the 
animal was injected with a normal dose o f nanorods. The half-life was observed to be 
approximately 58 minutes. After the clearance o f the nanorods, the animal was injected 
with ?i-carrageenan before the nanorods, and blood concentration measurements were 
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Figure 6-1: The effect o f X,-carrageenan on circulation half-life o f nanorods. The half- 
life for the first injection (without the A.-carrageenan injection) was 58.10 mins. The half- 
life for the second injection immediately following a A,-carrageenan injection was 110.55
mins.
Similar effects were observed in Case C where an animal was intravenously 
injected with A.-carrageenan directly followed by a normal dose o f nanorods. The peak 
concentration was not affected, as shown in Figure 6-2, while the clearance rate
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(according to a single decay exponential model) o f the nanorods from circulation went 
down from .00968 m in'1 to 0.00216 m in'1. This caused the half-life to he 321 minutes, as 





y = 3.68300e 
R2 = 0.98144 
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Figure 6-2: The circulation half-life o f nanorods after a X-carrageenan injection. It was 
observed that the peak concentration o f the nanorods was not affected after the injection 
o f X-carrageenan, while the clearance slowed down, and thus circulation half-life went 
up.
The second case o f the experiments (CASE B) was designed to investigate the 
effect o f the X-carrageenan injection after the introduction o f nanrods in the circulating 
blood. For this experiment, a dose o f X-carrageenan was intravenously injected into an 
animal during the clearance phase, and the projected half-life o f the nanorods before and 
after the injection were compared. It was observed that the clearance went down from
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000868 m in'1 to 0.00225 m in'1 and the half-life increased from approximately 80 minutes 
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Figure 6-3: The elongation o f circulation time o f nanorods after the introduction o f X- 
carrageenan into the circulation.
6.4 Discussion
The purpose o f this set o f pilot experiments was to establish the feasibility to X- 
carrageenan as an adjuvant therapy that could be used for RES blockade, ultimately 
increasing the AUC o f the plasma concentration to help improve accumulation in the 
tumors. These preliminary experiments showed that X-carrageenan could be used as a 
RES blockade agent to increase the circulation time o f the nanorods in a murine model. 
The findings o f this study demonstrate the utility o f X-carrageenan in increasing the 
circulation half-life and AUC o f PEGylated gold nanorods. In addition, the use o f X- 
carrageenan after nanorods injections was able to increase AUC values. These findings 
are noteworthy for investigators who wish to achieve the longer circulation times without
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particle modification. The data from these preliminary experiments was used to design a 
larger study on the effect o f X-carrageenan on circulation o f nanoparticles. During the 
design o f those experiments, it was theorized that the change in volume o f distribution 
caused by the bolus injection o f X-carrageenan before nanorods could be affecting the 
clearance. Those concerns were addressed by adding a control group where equal volume 
o f saline (as X-carrageenan) was injected to the animal in the control group. T his enabled 
the investigators to account for the change in AIJC caused by the change in volume o f 
distribution o f the particles.
6.5 Review of Specifications
These preliminary experiments showed that X-carrageenan could be used as an 
RES blockade agent to increase the circulation time o f nanorods in a murine model. The 
findings o f this study demonstrated the utility o f X-carrageenan in increasing the 
circulation half-life and AUC o f PEGylated gold nanorods.The data from the subsequent 
experiments was presented (presentation title: “ The Use o f Real-Time Optical Feedback 
to Improve Outcomes” ) at Photonics West BiOS on February 2, 2014. with an associated 
conference proceedings publication, [86] and is the data set for an in-progress publication 
titled “ Suppression o f the Reticuloendothelial System Using X-Carrageenan to Prolong 
the Circulation o f Gold Nanoparticles'’. The specifications are described in Table 6-1. 
Table 6-1: Review o f specifications.
RES modulation 
Provide a means to 
modulate the AUC and clearance 
to increase exposure time o f 
nanoparticles.
Develop a safe protocol for temporary 
RES blockade for the modulation o f AUC, and 
eventually to increase treatment efficacy
CHAPTER 7
USE OF PULSE PHOTOMETER FOR 
IN  VIVO DETECTION 
OF QUININE
7.1 Introduction and Specifications
The novel multi-wavelength photoplethysmograph (PPG), discussed in previous 
chapters, was used to demonstrate the potential to enhance therapeutic treatment 
predictability as pharmacokinetic metrics are provided throughout the intravenous 
delivery phase o f quinine in real-time. The drug currently under investigation is anti- 
malarial quinine which has an absorption peak at around -350 nm. The algorithm was 
adapted to quantify the concentration o f quinine in the pulsatile, circulating blood based 
on its extinction at three wavelengths (355, 660 and 940 nm). We show an example o f the 
system collecting data representing the baseline, injection, and the clearance phases. An 
examination o f the raw signal suggests that the system is well suited to sense the 
concentration o f quinine in the therapeutic range (10 mg/kg).
The initial rationale for developing this type o f instrument relates to the need for 
increased quality and reproducibly o f nanoparticle-based therapies. The PPG quantifies 
the concentration using the Beer-Lambert law and the principles o f pulse oximetry 
theory, focusing on the optical density o f the pulsating medium measured in a
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vascularized mass o f tissue. This was implemented to find the concentration o f gold 
nanoshells in vivo in the murine models across the therapeutically relevant concentration 
range [24], The device uses off-the-shelf optoelectronic components in conjunction with 
a LabVIEW virtual instrument (V I) with an algorithm based on Beer-Lambert's Law in a 
multi-spectral method designed to elucidate the concentration (in optical density) o f oxy- 
and deoxy-hemoglobin and the nanoparticles simultaneously in the blood. This device 
was implemented to measure the in vivo concentration o f the particles that are absorbent 
between 600 -  940 nm, longer than the major absorptive bands o f hemoglobin.
We speculated early in the development process that the opto-electronic system, 
as well as the intrinsic algorithms, should be versatile enough to sense traditional 
therapeutic agents not based on particle formulations. Potential compounds must contain 
optically absorptive bands in the water window between 200 and 900 nm, such as 
doxorubicin (absorption peak -460 nm, fluorescent emission peak -600 nm). quinine 
(absorption peak -350 nm, fluorescent emission peak -460 nm), and many o f the agents 
used in photodynamic therapy.
A major concern dealt with the ubiquitous presence o f hemoglobin, and how its 
absorptivity below 600 nm might confound the sensing o f agents with absorption in that 
spectral region. We decided to examine quinine, focusing on the current clinical needs 
related to maintaining the dose within the therapeutic window and concerns o f potential 
toxicity. Plasma quinine concentrations above 15 mg/1 were associated with increased 
risks o f permanent visual damage and o f cardiac arrhythmias [88]. The selection was also 
a test o f the versatility o f the system, as the compound absorbs strongly around 350 nm,
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corresponding with hemoglobin absorbance two-orders o f magnitude greater than 
previously examined.
The award that funded this research presented aims that would demonstrate the 
potential benefits o f integrating the PPG with established therapies. The aims are to 
improve treatment reproducibility as we precisely control and verify the delivered dose, 
as well as quantify the clearance properties o f the drug in real-time allowing for better 
control o f the dose within the therapeutic window. This report presents the feasibility test 
o f the system to quantify the concentration o f quinine, delivered intravenously at a 
therapeutically relevant dose.
7.2 Materials and Methods
7.2.1 Instrumentation
A combination o f a multivibrator chip (CD4047BCN) configured in an astable 
free running mode producing pulses at a rate o f 1.19 MHz and a 3-bit counter 
(MM74HC393N) are used to feed the signal into a 3-to-8 decoder (MM74HC138N). The 
decoder separates pulses among eight different channels, each generating pulses at the 
rate o f approximately 150 pulses/sec with a duty cycle o f approximately 15%. The pulses 
from the decoder are sent to buffers (LM324N) to supply power to our light sources.
The circuitry o f the pulse photometer is designed to use up to eight channels o f 
data collection. We used three data collection channels and one ambient light subtraction 
channel for our experiments. After the collection o f the PPG o f the mouse, the pulses are 
inverted, using an inverter (MM74HC04N), which controls sample and hold chips (LF 
398), one for each data channel and subtraction channel.
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The signals from the sample-and-hold chips are then fed through a first order 
analog filter (Fc = 28 Hz) for smoothing and attenuation o f the power line interference 
and then digitized with an NI DAQ card set to a sampling rate o f 10 kHz.
The probe, a transmission-mode “ clip” , looks similar to many commercially 
available veterinary pulse oximeters clips made for the tail, paw. or leg o f a murine 
subject. Major components consist o f a photodiode (Hamamatsu S1337-33BR) and 
LHDs (Roithner LaserTechnik UVT0P335-HL-T039 and LED660N/940-04A). These 
LEDs are o ff the shelf opto-electronic components that contain wavelengths o f 340 nm, 
660 nm, and 940 nm. The 340 nm wavelength was chosen to match the maximum 
extinction peak o f the quinine used.
7.2.2 Algorithm
The pulse photometer algorithm is implemented in a LabVIEW VI. The signal 
from the subtraction channel is first subtracted from each o f the other channels to account 
for ambient light interference. A band-pass filter with user specified order and cutoff 
frequencies is utilized to extract the pulsatile portion o f the PPG referred to at the AC 
signal.
The AC magnitude o f the PPG is determined by the envelope o f this signal. An 
averaging algorithm is used to extract the baseline or DC portion o f the PPG. These 
values can be used to determine the extinction change due to pulsation at each 
wavelength using the Beer-Lambert Law as follows,
where the ratio o f A A at two wavelengths can be calculated, which eliminates the 
wavelength dependence o f the measurements.
Eq. 7-1
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Further manipulation o f the Beer-Lambert Law yields equations that are 
dependent only on the effective attenuation coefficients o f reduced and oxygenated whole 
blood and the ratiometric pulsatile changes referred to as Rxi/X2 where A1 and A2 are the 
interrogation wavelengths:
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and the ratio for the second set o f wavelengths is shown as
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Summing the absorbances at the wavelengths, we get two equations as follows,
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Simultaneous solving o f these two equations yields estimates o f both Quinine an^ 
S, where S is the oxygen saturation. Five second averages o f the AC and DC magnitudes 
at each wavelength are computed and used to solve the system o f equations to determine
Rquinine
7,2.3 Animal Experiments
A ll animals were handled and cared for in accordance with the Louisiana Tech 
Institutional Animal Care and Use Committee. Three male albino mice (20-25 g), o f 
undetermined genetic characteristics were used in this study.
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Each mouse was placed under anesthesia using isollurane vaporized at three 
percent concentration as set by the vaporizer (Dentry Biomedical) with 95% oxygen 
(Invacare 5) delivered at a flow rate o f 1.5 L/min to a small plastic enclosure.
Once immobilization was achieved, the mouse was moved to a temperature 
controlled heating pad (Physitemp TCAT-2LV. controller) set to 38°C and the feedback 
thermometer was placed under the abdomen. Anesthesia was maintained by delivering 
isofiurane at a concentration o f 20% o f that used to induce immobilization via a snout 
cone.
The tail vein was then catheterized in order to deliver the quinine injection. Once 
the thermometer measured a temperature o f around 39°C, the probe was placed on the 
mouse’s tail and allowed to collect the photoplethysmograph data for a period o f 30 
seconds at a time.
Once signals at each wavelength met the typically used metrics o f signal quality 
(AC amplitudes o f 5 mVp-p with standard deviations o f less than 0.08 over the five 
second average), an injection o f 80 pL quinine sulphate solution was given at the 
concentration o f 3.23 pg/mL in 0.9 % saline solution.
A dose o f quinine, corresponding to approximately 12 pg/gm was delivered 
intravenously. The pulse photometer was allowed to collect estimates o f iuquinine and S 
for five minutes after the injection phase, then removed briefly, and a final set o f data 
meeting the previously described signal criteria was collected.
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7.3 Results
The PPG recorded a pulsatile signal across the mouse tail, which demonstrates the 
transillumination o f the tissue, with light hitting the photodiode, (around 3mm path 
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Figure 7-1: The pulsatile part o f the photoplethysmogram signal (a) before injection (b) 
during and after injection. The ratiometric measurements o f the three channels 
(w ithl^_p >  5mV) were collected and used to calculate the in vivo concentration o f 
quinine.
After the introduction o f quinine in the blood stream, an increase was observed in 
the peak-to-peak amplitude o f the AC signal at 340 nm, as demonstrated in Figure 7-1 as 
anticipated, compared to the red (660 nm) and infra-red light (940 nm). The magnitude 
o f the AC portion o f the signal corresponds to the respective extinction in the 
corresponding wavelengths, and should increase as the optical extinction at a specific 
wavelength increases. A common maintenance dosage o f intravenous quinine solution is 
10 mg/kg [9],
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The PPG was run in continuous mode before, during, and after the intravenous 
delivery, and showed a peak concentration o f ~ 7 optical density (OD), as shown in 
Figure 7-2.
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Figure 7-2: The real-time in vivo concentration o f quinine in blood. The graph is divided 
into three parts: (1) Background data from pre-injection phase (2) The rising 
concentration during the injection, and (3) The decay phase after the end o f the injection.
From the graph, it was observed that the concentration o f quinine in the blood 
rises from the background (Part 1) during the injection phase (Part 2). The decay 
observed in the in vivo concentration starting at the end o f the injection (Part 3) suggests 
that the quinine was starting to be metabolized or cleared as would be expected. 
Previously, it was shown that the relationship between the concentration o f an absorber in 
pulsatile blood and the optical density (concentration) readings measured by the device is 
linear [24],
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An empirical calibration using blood draws and UV/Vis absorbance spectroscopy 
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Figure 7-3: The comparison between the results o f blood analysis (UV/Vis) and the PPG 
readings o f intravenously injected quinine. The graph represent the PPG readings that 
were taken at different time points after the injection, plotted against the UV/Vis analysis 
o f the blood draws at the same time points (n = 3 mice, 8-9 points from each mouse). 
Linear fit resulted in a straight line with the equation: y = 1.032x-.1604, R2=0.96
The peak OD shown for the relatively “ normal"’ dose suggests that this compound 
is well suited for the dynamic range o f the device with nanoparticles, previously 
calculated to be 0.5 - 8 OD.
7.4 Discussion
This report suggests that the pulse photometer can be adapted for use towards the 
in vivo detection o f circulating drugs with distinct absorption bands in the range o f 200-
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800 nm, corresponding to the low absorptivity o f water in this specified region. This 
instrumentation could have clinical utility in support o f drugs about which the knowledge 
o f the initial or maintenance dose, circulation characteristics, and therapeutic window 
would be helpful or critical.
CHAPTER 8
USE OF PULSE PHOTOMETER FOR IN  VIVO 
DETECTION OF AMPHOTERICIN B
8.1 Introduction and Specifications
Previous experiences related to the development o f optically-absorptive 
nanoparticles for in vivo therapeutic applications led the team to appreciate the value o f 
real-time pharmacokinetics [24, 89], A real-time system allows for a precise dose to be 
achieved, and allows for an analysis o f the clearance rate providing information related to 
the functioning o f the physiological systems o f the subject and the characteristics o f the 
drugs or nanoparticles in use. Employed in a closely related inbred mouse group, real 
time pharmacokinetics can lend credibility to other metrics demonstrating the therapeutic 
agent has been manufactured according to specifications and functions in vivo as 
expected.
This chapter describes our initial investigation o f the feasibility o f our prototype 
towards amphotericin b (ampB), an anti-fungal agent. Given the significant mortality and 
morbidity o f invasive fungal infections, and considering the significant challenges ampB 
poses in regards to its own toxicity, we present here a demonstration o f real-time 
pharmacokinetics to medical practitioners who are faced with the challenges o f high 
doses and/or long-term use.
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The Center for Disease Control (CDC) reports candidiasis as the fourth leading 
cause o f hospital-acquired infections in the United States [90]; however, for children and 
neonates, it is the third most frequent etiology o f hospital-acquired infections in the 
United States and in Europe [91], This is significantly influences the high mortality rate 
among premature infants (~ 30% for those born weighing less than 1000 grams) [92], 
AmpB is also widely indicated in oncology, immunology, and hematology, where 
hematopoietic stem-cell transplants are routinely utilized. Associated toxicity and 
therapeutic levels have been investigated for Amphotericin B used in prophylaxis for the 
highly immunosuppressed patients population undergoing hematopoietic stem cell 
transplants [93], Amphotericin B is also applied to visceral leishmenaisis, which is fatal i f  
untreated, affecting nearly half a million individuals annually [5],
While population-based half-life or peak levels provide for dosing 
recommendations and frequencies for a given pharmacological agent, no one individual 
with a given disease can be expected to process pharmacologic agents in an identical 
manner, lending many o f the pharmacologic treatment decisions to a best estimate. The 
method presented here using an animal model suggests a tool or methodology to study 
pharmacological agents with significant toxicity while optimizing dose related efficacy, 
metabolism and clearance, and other relevant pharmacokinetic concerns. The PPG system 
utilized quantifies the concentration o f the agent under observation using the Beer- 
Lambert Law and the principles o f pulse oximetry theory, focusing on the optical density 
o f the pulsating medium measured in a vascularized mass o f tissue. The device uses off- 
the-shelf optoelectronic components in conjunction with a LabVIEW virtual instrument 
(V I) with an algorithm based on Beer-Lamberf s Law in a multi-spectral method
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designed to elucidate the concentration (in optical density) o f oxy- and deoxy­
hemoglobin and the nanoparticles simultaneously in the blood. This device was initially 
demonstrated to measure the optical density o f the nanoparticles that are absorbent 
between 600 -  940 nm. in the range o f wavelengths longer than the major absorptive 
bands o f the hemoglobin.
We speculated early in the development process that the opto-electronic system, 
as well as the built-in algorithms, should be versatile enough to sense traditional 
therapeutic agents not based on particle formulations. Potential compounds must contain 
optically absorptive bands in the water window between 200 and 900 nm, such as 
doxorubicin (absorption peak -460 nm, fluorescent emission peak -600 nm), 
amphotericin b (absorption peak -355 nm, fluorescent emission peak -460 nm), and 
many o f the agents used in photodynamic therapy.
A major concern dealt with the ubiquitous influence o f hemoglobin upon the 
pulse-derived signal, and how its absorptivity below 600 nm might confound the sensing 
o f agents with absorption in that spectral region.
The award that funded this research proposed to demonstrate the potential 
benefits o f integrating the PPG with established therapies. The major aim, as presented 
here, demonstrates an optical sensing system that can provide improvements in treatment 
reproducibility via delivery control and allow for control o f the circulating dose within 
the pharmacological therapeutic window. This report presents the feasibility test o f the 
system to quantify the circulating concentration o f amphotericin B, in the liposome-based 
Abelcet® formulation, delivered intravenously in a murine model at a therapeutically 
relevant dose.
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8.2 Materials and Methods
8.2.1 Instrumentation
A combination o f a multivibrator chip (CD4047BCN) configured in astable free 
running mode producing pulses at a rate o f 1.19 MHz and a 3-bit counter 
(MM74HC393N) are used to feed the signal into a 3-to-8 decoder (MM74HC138N). The 
decoder separates pulses amongst eight different channels, each generating pulses at the 
rate o f approximately 150 pulses/sec with a duty cycle o f approximately 15%. The pulses 
from the decoder are sent to buffers (LM324N) to supply power to our light sources.
The circuitry o f the pulse photometer is designed to use up to eight channels o f 
data collection. We used three data collection channels and one ambient light subtraction 
channel for our experiments. After the collection o f the PPG o f the mouse, the pulses are 
inverted, using an inverter (MM74HC04N), which controls the sample and hold chips 
(LF 398), one for each data channel and subtraction channel.
The signals from the sample-and-hold chips are then fed through a first order 
analog filter (Fc = 28 Hz) for smoothing and attenuation o f power line interference and 
then digitized with an NI DAQ card set to a sampling rate o f 10 kHz. The probe looks 
similar to many commercially available veterinary pulse oximeters clips made for the tail, 
paw, or leg o f a murine subject.
Major components consist o f a photodiode (Hamamatsu S1337-33BR) and LEDs 
(Roithner LaserTechnik UVT0P335-HL-T039 and LED660N/940-04A). These LED’s 
are o ff the shelf opto-electronic components that contain wavelengths o f 355 nm, 660 
nm, and 940 nm. The 355 nm wavelength was chosen to match the maximum extinction 
peak o f the amphotericin b used.
83
8.2,2 Algorithm
The pulse photometer algorithm is implemented in a LabVlFW VI, where signal 
from the subtraction channel is first subtracted from each o f the other channels to account 
for ambient light interference. A band-pass filter (fourth order Butterworth filter) with 
cutoff frequencies at 4 Hz and 10 Hz is used to extract the pulsatile portion o f the PPG 
referred to at the AC signal from the three channels. The AC magnitude o f the PPG is 
determined by the envelope o f this signal. An averaging algorithm is used to extract the 
baseline or DC portion o f the PPG. These values can be used to determine the extinction 
change due to pulsation at each wavelength using the Beer-Lambert Law.
AA i  = log Eq. 8-1
\V|x-VAc/ i  vocA
The ratio o f AA at two wavelengths can be calculated which eliminates the 
wavelength dependence o f the measurements. Further manipulation o f the Beer-Lambert 
law yields equations that are dependent only on the effective attenuation coefficients o f 
reduced and oxygenated whole blood and the ratiometric pulsatile changes referred to as 
1 /A2 where A l  and A2 are the interrogation wavelengths:
R 355 / 9 4 0 ~  Eq. 8-2
vnc940
and the ratio for the second set o f wavelengths is
L 660
R w /9« = ^ -  Eq- 8-3
VDC94o
Combining the absorbance from the two channels in ratio metric form yields two 
simultaneous equations (Equation 8-1 and Equation 8-2), which can be solved by a linear
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algebra to calculate the values o f the two unknowns, and the ratios are calculated from 
the data collected from the photodiode (sensor).
p _ S(̂ YboJ + ̂ -SK̂ Hb04Manib „  „ .
R,55,,4,,% c , E q ’ 8 ' 4  
s(„SI1!)hi-s)(),S“)*c .' q '
Simultaneous solving o f these two equations yields estimates o f both and S, 
where S is the oxygen saturation. Five second averages o f the AC and DC magnitudes at 
each wavelength are computed and used to solve the system o f equations to determine
Ulmb and S-
8.2.3 Animal Experiments
A ll animals were handled and cared for in accordance with the Louisiana Tech 
Institutional Animal Care and Use Committee (IACUC). Three female research albino 
mice (24-27g), o f undetermined genetic characteristics was used in this study. The mouse 
was placed under anesthesia using isoflurane vaporized at 3% concentration as set by the 
vaporizer (LEI Medical, Model M 3000) with 95% oxygen (Invacare 5) delivered at a 
flow rate o f 1.5 L/min to a small plastic enclosure.
Once immobilization was achieved, the mouse was moved to a temperature 
controlled heating pad (Physitemp TCAT-2LV, controller) set to 38° C and the feedback- 
thermometer was placed under the abdomen.
Anesthesia was maintained by delivering isoflurane at a concentration o f 20% o f 
that used to induce immobilization via a snout cone. The tail vein was then catheterized 
in order to deliver the injection.
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Once the thermometer measured a temperature o f > 39° C, the probe was placed 
on the mouse's tail and allowed to collect the PPGs. Once signals at each wavelength met 
typically used metrics o f signal quality (AC amplitudes o f 5 mVp-p with standard 
deviations o f less than 0.08 over the five second average), an injection o f 25 pL 
Abelcet® solution was given at the concentration o f 5 mg/mL in 5% dextrose solution. 
125 pg o f Abelcet® was delivered intravenously, corresponding to ~ 5.2 pg/gm.
The pulse photometer was allowed to collect estimates o f pamb and S for different 
time points after the injection phase, was then removed briefly, and a final set o f data 
meeting the previously described signal criteria was collected.
8.2,4 Blood Analysis
After each PPG reading, a blood sample was collected from the animals to 
compare the PPG readings with the analysis o f the blood sample using blood 
spectrometry. This simple UV-VIS assay was conducted by diluting 5 pL o f blood 
extracted from the tail vein into 995 pL o f a 10% Triton-X solution to lyse scattering 
confounders such as red blood cells.
The extinction o f the amphotericin b at 355 nm, after subtraction o f the 
hemoglobin baseline, was quantified. The subtraction o f the hemoglobin baseline was 
done by using the value o f the peak at 560 nm (between the hemoglobin bands).
The blood samples were processed in UV-transparent micro- cuvettes [Brandtech 
(Essex, Connecticut) Ultra-Micro] in a low-volume spectrophotometer [DU 800,
Beckman Coulter]. The corresponding values obtained from the UV/Vis analysis were 
plotted against the PPG values to generate a calibration curve.
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8.3 Results
The PPG device was used to quantify the in vivo concentration o f Abelcet® in 
near-real time. Blood draws corresponding to the PPG readings were also taken and 
analyzed using a UV/Vis spectrometer. The data points were taken at fixed time intervals 
after the injection to produce a bio-availability curve fitted with a single decay 
exponential model, as shown in Figure 8-1.
▲ U V /V is  
•  PPG
 Expon. (U V /V is )
- - - - -  Expon. (PPG)
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Figure 8-1: Bioavailability curve o f Abelcet ® in vivo as measured by the PPG (R2 = 
0.95) and the blood draws by UV/Vis analysis (R2 = 0.93). The values were then fitted to 
a single decay exponential model to obtain half-lives. (UV/Vis = 355 min, PPG = 398 
min.)
A single exponential decay model was used to describe the clearance o f the drug 
from the blood, which produced a circulation half-life for Abelcet® in the blood. The 
average circulation half-life as measured by the PPG and blood draws were measured to 
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The calibration curve generated by using the data against UV/Vis spectrometry is 
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Figure 8-2: The comparison between the results o f blood analysis (UV/Vis) and the PPG 
readings for intravenously injected Abelcet®. The graph represent the PPG readings that 
were taken at different time points after the injection, plotted against the UV/Vis analysis 
o f the blood draws at the same time points (n = 3 mice, 7-8 points from each mouse). 
Linear fit resulted in a straight line with the equation: y = 0.85x + 0.41.
8.4 Discussion
The calibration curve demonstrates an underestimation o f higher concentrations 
and overestimation at lower concentrations o f circulating Abelcet®, which is similar to 
the work previously reported. This experimental bias in the instrument can explain the 
variation o f the PPG half-life from the UV/Vis half-life. The range o f concentrations that 
was detected by the PPG was experimentally determined to be 0.0987 mg/mL in the 
blood (=4 OD) to 0.025 mg/ml in the blood. This range o f values demonstrates that the 
device is feasible for in vivo detection o f a clinical amphotericin dose.
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8.5 Conclusion
Given the challenges in identifying the therapeutic levels required to achieve the 
effectiveness in various conditions that necessitates ampB, the known adverse effects 
associated with it. and continued investigations for ampB use in complex patients, the 
ability to sense the real time in vivo concentration o f Abelcet® could have significant 
clinical implications. In addition, the theory o f pulse dye densitometry and pulse 
plethysmography can be applied towards non-invasive detection and pharmacokinetics o f 
other molecular drugs with similar spectral properties.
CHAPTER 9 
CONCLUSIONS AND FUTURE WORK
This body o f work demonstrates the development o f various instrumentation and 
protocol improvements to pre-clinical and clinical outcomes. Closing the gap between the 
developed pre-clinical practices (in an academic setting) and pre-clinical and clinical 
setting (in industry) is part o f future work that is necessary for a set o f best practices to 
fully develop. The primary goal o f these recommendations is improved clinical 
outcomes. The primary work toward improved clinical outcomes is developed through:
•  Development o f instrumentation for proper dose verification during the 
treatment, and continued observation throughout the clearance to 
minimize the chances o f untoward reactions.
• Protocols for treatment decisions through observation o f clinical signs 
(real-time blood plasma concentration and rapid elemental analysis o f 
biopsied tissue
• Quantifying influential factors that affect final outcome (i.e. accumulation 




The development and the use o f the pulse photometer have been evaluated, and 
modified as needed for use with PEGylated gold nanoshells and nanorods. The 
instrumentation and data analysis protocols discussed in this work emphasize the ability 
to process data in near real time. The importance o f standardized data analysis and 
monitoring is found primarily when future protocols use these devices to inform clinical 
decisions in real time. Early academic or pre-clinical studies have the luxury o f time for 
making decisions, but clinical decisions w ill be made using this information in an urgent 
and life threatening climate. The climate these decisions w ill be made in highlights the 
need for standardized and easily interpreted results. The path toward data driven 
medicine w ill involve the personalized one compartment modeling from real-time blood 
plasma monitoring, and the ability to observe tumor uptake metrics. The ability to collect 
tumor uptake data is available through rapid elemental analysis.
The proposed rapid elemental analysis technique (EDXRF used in this work) 
allows for the quantitative analysis o f gold in animal tissues. With a focus on future 
clinical implementation, elemental analysis w ill be required to be completed in under 12 
hours. The current 12-hour window is based on timing o f currently implemented clinical 
treatment protocols. This elemental analysis technique meets these requirements, and 
continues to be used in our animal research due to its ease o f use and short turnaround 
time. Additional quantitative studies would be required to fully validate the technique and 
characterize the sources o f errors in the protocol prior to human clinical use.
In advance o f the implementation o f industry standard population 
pharmacokinetic modeling techniques, the pulse photometer and current M ATLAB 
coding were able to create individualized pharmacokinetic models. These individual one-
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compartment pharmacokinetic models are designed for near-real-time clinical 
implementation. The personalized one-compartment models provide the ability for 
comparison o f physiological responses to the treatment and allow us to head toward 
personalized cancer treatments. The population pharmacokinetic models can assist any 
clinical treatment with ongoing pre-clinical and clinical trials, and provide useful starting 
point information tailored to the patient (provided from the population pharmacokinetic 
models).
Future work should build on the set o f one-compartment models to create a 
desired blood plasma concentration curve. From the desired curve there is potential for 
the implementation o f traditional electrical engineering controls methods [79] to attempt 
to ensure a uniform blood plasma concentration curve. In future clinical settings, it w ill 
be possible for the delivery o f nanoparticles to be different and contain new dosing 
strategies to ensure optimization o f tumor uptake. Similar instrumentation can be used for 
dose verification and in vivo monitoring o f other clinically relevant drugs. In addition to 
the ability to create a more uniform blood plasma concentration curve from patient to 
patient, the one-compartment models w ill be able to assist with the detection o f undesired 
reactions (e.g. anaphylaxis) for different clinically relevant drugs, including the 
nanoparticles. As future studies search for improving clinical outcomes, the 
instrumentation, analysis protocols, and specifications discussed here can be useful as a 
starting point.
APPENDIX A 




Blood draws taken from a mouse post injection o f nanoshells can be used to 
measure the concentration o f circulating nanoshells. UV-Vis spectra o f the diluted blood 
draws can be analyzed using Beer’s Law to separate extinction caused by the 
oxyhemoglobin and nanoshells in the sample. This is done by observing the value at the 
peak extinction wavelength for nanoshells and by using Eq. A - l :
Apeak = ( i NSCNS+ f Hb()2Qlb02)D. Eq. A -l
Where A is the extinction at the peak wavelength, the s 's are the extinction 
coefficients for the two compounds o f interest (oxyhemoglobin(compound b) and 
nanoshells (compound (a) in this case) at the peak wavelength, and cns and cnt,0 2  are the 
concentrations nanoshells and Hb02. Note that we are using the extinction coefficient 
for oxyhemoglobin because the blood samples have been exposed to air in the sampling 
process. Therefore, we assume that the hemoglobin is fully oxygenated. Also, note that 
the extinction is pathlength dependent, but we assume that D is one centimeter.
The concentration o f nanoshells in the sample can be expressed using Eq. A-2:
r , _  Apeak" 1 HKxTllbo:
'-N S  •
f NS
Eq. A-2
A .1.1 Finding the Extinction Coefficients for Nanorods
Since Beer’s Law expresses concentrations as moles/liter, we w ill examine the 
nanorods as i f  each one was one atom. Therefore, you w ill notice that the molarities o f 
nanorods that are found in each sample are extremely low, but since they are such good 
extinguishers o f light, their molar extinction coefficients w ill be extremely high. As 
reported, batches o f nanorods are manufactured to have a peak optical density o f 100 at a
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wavelength between 760 and 820 nm. The molar extinction coefficient is found using 
Eq. A-3:
_ A ns
1 NS~ CNS ■ Eq. A-3
The concentration o f the nanoshells is reported as a number o f particles/ml. We
can find a molarity from Eq. A-4:
NP's ^ 1000ml + mol _  moles NP's Eq. A-4
ml IL  6 .02* 1023 NP's L
A. 1.2 Blood Draws and Measurements
Once the extinction coefficient used in Eq. A -l and Eq. A-2 is found, we can 
inject nanoparticles into a mouse, take blood samples, and examine them. The procedure 
for taking a blood sample and analyzing it is as follows:
1. Fill a micro-cuvette with 95 pi o f 10% Triton-X 100. Blank the spectrometer 
using that micro-cuvette.
2. Heparinize a ten microliter pipette tip by sucking in five microliter o f heparin and 
then releasing it leaving a layer o f heparin inside the tip.
3. Obtain a five microliter blood sample using the heparinized tip and mix this with 
the Triton-X in the cuvette.
4. Scan this cuvette using the previously specified wavelengths (500-11 OOnm) and 
record the extinction at 805 nm (Let’s say that is p805 ).
5. Dilute the sample using 100 pi Triton-X and scan again and record the extinction 
at 560 nm (p560).
6. Note that the hemoglobin “ crest”  is visible at around 560 nm.
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7. The formula for optical density is as follows, in Kq. A-5:
( " « - ( tX ) * 2* 840) ’ 20= ° d ' Eq. A-5
A.2 Adjustments




A.3 Calibration Curve/Typical Results
The spectra from blood draws taken from a mouse injected with nanoparticles can 
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Figure A -l: Extinction spectra o f blood prior to (raw blood) and post (all other 
spectra) injection. Note how the extinction at 760 nm increases greatly in comparison 






















Figure A-2: Calibration curve comparing the calculated nanoshell concentration in 
samples containing blood and nanoshells to samples containing only known 
concentrations o f nanoshells. The equation o f the linear fit is y = 0.667 lx  + 5E+08
APPENDIX B
ESTIMATION OF THE LIMITS OF DETECTION 
OF AN LED DETECTOR COMBINATION
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This addendum describes the process o f roughly estimating the upper lim it o f 
detection for a known set o f LED and detectors. In this example, the theoretical upper 
lim it o f detection for the 805 nm led o f the four wavelength package L660/735/805/940- 
40B42-C-1, and S1227-33BR. The output power o f the LED at 805 nm is rated at 3.5 
mW. The datasheet can be obtained from the link that follows:
[http://www.tech-led.com/data/L660.735.805.940-40B42-C-I.pdl].
The spectral response chart shows that and the noise equivalent power (NEP) is o f 
the photodiode is 2.1X 1 O'15 W/Hzl/2, and the peak spectral response 0.43 A/W and 
spectral response at 805 nm is 0.4 A/W.
We know, the minimum detectable power:
NEP*Rmax*VB „  „  ,
e " - b - '
where, Pmin is the minimum detectable power with the photodiode with a SNR o f 1
NEP is the noise equivalent power
Rmax ’s the maximum responsivity o f the detector
R(X) is the responsivity o f the photodiode at the LED wavelength
B is the measurement bandwidth
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Using 12 kHz as the bandwidth (approximate value for the pulse photometer), we 
get the minimum detectable power to be 2.47 X lO'13 W. Now. let's suppose the incident 
power from LED at optimum conditions is 3.5mW. Therefore under the best conditions, 
the maximum theoretical lim it o f detection for this set is:
A= log = i 1.14 OD






Avertin is useful for use in procedures where immobilization is less than 20 
minutes and with no significant pain or distress. Avertin should provide good skeletal 
muscle relaxation and a moderate degree o f respiratory depression.
C.l Contraindication
Repeated administrations o f avertin are contraindicated.
Do NOT inject intravenous, animal death would be expected within minutes.
C.2 Materials
2,2,2-tribromoethanol (Sigma-Aldrich T48402)
2-Methyl-2-Butanol (Alfa Aesar A 18304)
C.3 Avertin Stock Solution
Mix:
1. 15 g 2,2,2-tribromoethanol
2. 15.5 mL 2-Methyl-2-Butanol
3. M ix overnight in a dark (amber) bottle at room temperature, (be sure to use clean
stir bar)
The stock solution has a shelf life o f six months when stored and wrapped in foil 
in a dark cabinet at room temperature. The following information MUST be on the 
outside o f the bottle and the box the bottle is stored in: Solution, Expiration date, grams 
o f 2,2,2-tribromoethanol and lot number, mL 2-Methyl-2-Butanol and lot number.
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C.4 Avertin Working Solution
Mix:
1. 0.1 mL Avertin Stock Solution
2. 7.9 mL 0.9% Sterile Saline
3. Mix in a dark bottle and store overnight
4. Filter sterilize with 0.22 [am filter, label and store at four to six degrees Celsius. 
Working solution has a shelf life o f six months i f  unopened. Once the working
solution has been opened, it has a shelf life o f one week.
A ll containers o f working solution must be labeled with the following 
information: Solution, Expiration date (once opened), Date o f sterilization. Your Initials, 
mL Avertin stock solution, mL saline.
C.5 Animal Injection
Intraperitoneal (IP) injection o f Avertin solution is given at the following dose: 
Normal injection for slow particle infusion: 25 pL/g body weight.
APPENDIX D
INSTITUTIONAL ANIMAL CARE 




INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
Louisiana Tech University
25 October 2011
Dr. Patrick O ’Neal, Ph.D.
Biomedical Engineering 
Louisiana Tech University 
Campus Box # 58
Dear Dr. O ’Neal:
The Louisiana Tech University's Institutional Animal Care and Use Committee (1ACUC) met on 
17 October and approved your amended protocol entitled:
Nanoparticle Tracking For Cancer Therapy
The committee members feel that the transport of mice from Houston that have been inoculated 
with cancer cells is appropriate, and in keeping with your previous protocols. Please make sure 
that the animals are in a transport box with adequate water and that the vehicle be air-conditioned 
at all times so that the animals will not become dehydrated or overheated.
You and the students have been approved for a limit o f 50 animals in this initial study beginning 
1 November 2011. Please remember that you are required to keep adequate and accurate records 
of all procedures, results, and the number o f animals used in this protocol. You are required to 
provide a progress report each year by 1 October. I f  the project should need to be extended 
beyond 31 October 2014, the third year, you will be required to submit a new protocol. Any 
changes you need to make in the protocol before the termination date must be submitted to the 
1ACUC on the amendment form for approval before implementation.
Keep for your research records and results for three years after termination o f the project. These 
records must be available for review by the 1ACUC or state and federal animal use agencies.
Each year by 31 October you will be required to complete a summary o f number of animals used 
in this protocol used for the United States Agricultural Agency (USDA). Note that failure to 
follow this protocol as approved may result in the termination of research. I f  you have any 
questions please call me at 318-243-0796 or via e-mail atjgspauld@latech.edu.
.ouisiana Tech University IACUC
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INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
Louisiana Tech University
9 September 2013
Patrick O ’Neal, Ph.D.
Biomedical Engineering 
Louisiana Tech University 
Campus Box M 58
Dear Dr. O ’Neal:
The members of the Institutional Animal Care and Use Committee (1ACUC) have all read your 
protocol (Number2013-9) entitled: Nanoparticle Tracking huti mmmUtton Test. They have 
appointed me as the Designated Reviewer. 1 have read and approved your p«o»ocol.
Your protocol consists of two parts: (l)th e  use of animals fimn the Ih eh ftiB i that may require 
anesthesia. For this I recommend use of 
animals sedated during the non-invasive t
(2) The testing at the instrumentation on dogs 
the supervision o f Dr. Sexton DVM and any 
assist in his procedures. One important 
consent form” signed by the owners of I 
take care not to use any particular animal f it ’ 
interrupt the business of the facility.
You have three years in which to complete t 
by the IACUC by 1 October 2016. W *
2015. Please remember that you are 
procedures, results, and the number of atibhifo i*~  
termination o f the project. These records must bi t 
and federal animal use agencies. EatliyairbtC P*
summary o f animals used for the UaltedStatpy
to follow tWsprotocol as 
questions please call me at 318-243^1796 (
xufibe t **?
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Figure E - l: Bioavailability curve o f quinine in vivo as measured by the PPG (R2 = 0.989) 
and the blood draws by UV/Vis analysis (R2 = 0.943). The values were then fitted to a 
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Figure E-2: Bioavailability curve o f quinine in vivo as measured by the PPG (R2 = 0.985) 
and the blood draws by UV/Vis analysis (R2 = 0.971). The values were then fitted to a 
single decay exponential model to obtain half-lives in Mouse 2.
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Figure E-3: Bioavailability curve o f quinine in vivo as measured by the PPG (R2 = 0.987) 
and the blood draws by UV/Vis analysis (R2 = 0.954). The values were then fitted to a 
single decay exponential model to obtain half-lives in Mouse 3.
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and the blood draws by UV/Vis analysis (R2 = 0.931). The values were then fitted to 
single decay exponential model to obtain half-lives in Mouse 1.
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LOESS, originally proposed by Cleveland (1979) and further developed by 
Cleveland and Devlin (1988). specifically denotes a method that is more descriptively 
known as locally weighted polynomial regression. At each point in the data set. a low- 
degree polynomial is fit to a subset o f the data with explanatory variable values near the 
point whose response is being estimated. The polynomial is fit using weighted least 
squares, giving more weight to points near the point whose response is being estimated 
and less weight to points further away. The value o f the regression function for the point 
is then obtained by evaluating the local polynomial using the explanatory variable values 
for that data point. The LOESS fit is complete after regression function values have been 
computed for each o f the n data points. Many o f the details o f this method, such as the 
degree o f the polynomial model and the weights, are flexible. The range o f choices for 
each part o f the method and typical defaults are briefly discussed next.
LOESS combines much o f the simplicity o f linear least squares regression with 
the flexibility o f nonlinear regression. It does this by fitting simple models to localized 
subsets o f the data to build up a function that describes the deterministic part o f the 
variation in the data, point by point. In fact, one o f the chief attractions o f this method is 
that the data analyst is not required to specify a global function o f any form to fit a model 
to the data, only to fit segments o f the data [10].
The local polynomials fit to each subset o f the data are almost always o f first or 
second degree, that is, either locally linear (in the straight line sense) or locally quadratic. 
Using a zero degree polynomial turns LOESS into a weighted moving average. Such a 
simple local model might work well for some situations, but may not always approximate 
the underlying function well enough. Higher-degree polynomials would work in theory.
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but yield models that are not really in the spirit o f LOESS. LOESS is based on the ideas 
that any function can be well approximated in a small neighborhood by a low-order 
polynomial and that simple models can be fit to the data easily. High-degree polynomials 
would tend to over fit the data in each subset and are numerically unstable, making 
accurate computations difficult.
As mentioned above, the weight function gives the most weight to the data points 
nearest the point o f estimation and the least weight to the data points that are furthest 
away. The use o f the weights is based on the idea that points near each other in the 
explanatory variable space are more likely to be related to each other in a simple way 
than points that are further apart. Following this logic, points that are likely to follow the 
local model best influence the local model parameter estimates the most. Points that are 
less likely to actually conform to the local model have less influence on the local model 
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